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Abstract 
The µ-opioid receptor system is central to reward and pain relief across species. In rodents, 
injection of opioids into striatum amplifies ‘liking’ responses to and/or motivation for 
rewards. In humans, opioid agonists can induce euphoria, whereas antagonists reduce food 
reward. Brain regions implicated in reward processing such as the mesolimbic reward system 
are rich in µ-opioid receptors. We investigated the role of the µ-opioid receptor system in 
human reward processing using systemic manipulation with a µ-opioid receptor agonist 
(morphine). In a functional magnetic resonance imaging (fMRI) pilot study we developed test 
procedures to measure reward related brain activity to anticipation and delivery of rewards, 
and to minimise potential confounds related to the pharmacological manipulation. We 
predicted activity in in the ventral striatum during anticipation and delivery of reward in a 
modified monetary incentive delay (MID) task, and that this activation would be higher in the 
morphine condition compared to placebo. In a within-subjects, counter-balanced, placebo-
controlled, double-blind design, 11 healthy volunteers (4 females, mean age 26 ± 3 years) 
were tested on a battery of reward tasks on two separate days. In line with previous research, 
our version of the MID task yielded significant activation in the ventral striatum during 
anticipation and delivery of rewards, compared to baseline. We also observed an indication of 
higher activation in the morphine condition compared to placebo in the left ventral putamen 
during reward delivery. Control measures (subjective effects, motor coordination, 
physiological measures, and a visual fMRI paradigm) revealed minimal confounding effects 
of drug manipulation on task results. These results validate our test procedures and are in line 
with the hypothesis that systemic stimulation of the µ-opioid receptor system modulates 
activity in the ventral striatum during reward processing. The methods developed in this 
thesis will be used in the future study investigating the role of the µ-opioid receptor system 
for reward and motivation in the healthy human brain. 
MORPHINE EFFECTS ON MONETARY REWARD 
  
IX 
IX 
  
MORPHINE EFFECTS ON MONETARY REWARD 
  
X 
X 
Table of contents 
 
Introduction ................................................................................................................................ 1!
Reward circuitry in the brain .............................................................................................................. 2!
Neuroimaging studies of reward ......................................................................................................... 7!
The current study .............................................................................................................................. 11!
Methods.................................................................................................................................... 12!
Participants ........................................................................................................................................ 12!
Design ............................................................................................................................................... 13!
Drug administration .......................................................................................................................... 14!
Control measures .............................................................................................................................. 15!
Monetary incentive delay task development ..................................................................................... 17!
fMRI parameters ............................................................................................................................... 25!
Analysis............................................................................................................................................. 27!
Results ...................................................................................................................................... 30!
Subjective effects and control data ................................................................................................... 30!
fMRI results ...................................................................................................................................... 31!
Discussion ................................................................................................................................ 36!
Choice of regions of interest ............................................................................................................. 37!
Validation of the current MID paradigm .......................................................................................... 38!
Using the MID task to study morphine effects ................................................................................. 40!
Limitations and future research ........................................................................................................ 42!
Conclusion ............................................................................................................................... 44!
References ................................................................................................................................ 45!
MORPHINE EFFECTS ON MONETARY REWARD 
 
1 
Introduction 
Being able to navigate an environment relies on an individual’s ability to evaluate and 
predict future rewards and punishments, and use these predictions as well as past experiences 
to direct behaviour (O'Doherty, 2004). A reward can be defined as an event or a stimulus “for 
which an animal will perform an operant response” (Koob, 1992). Rewards elicit approach 
behaviour whereas punishments suppress behaviour and lead to avoidance (Porcelli & 
Delgado, 2009). When a value is associated with a rewarding stimulus, this leads to 
predictions of similar rewards in the future through learning mechanisms (Schultz, Dayan, & 
Montague, 1997). To integrate information about rewards and punishments to guide 
behaviour, the brain must have a way of evaluating rewards and attributing values to different 
stimuli (Porcelli & Delgado, 2009). These processes are attributed to a complex reward 
system in the brain (Berridge & Kringelbach, 2008). Disruptions in the brain reward system 
can have debilitating consequences, as evidenced in psychiatric disorders such as substance 
abuse, mood disorders, attention deficit/hyperactivity disorder (ADHD), and schizophrenia 
(Gold, Waltz, Prentice, Morris, & Heerey, 2008; Luman, Tripp, & Scheres, 2010; Naranjo, 
Tremblay, & Busto, 2001; Nestler, 2005).  
Reward as a process can be divided into different components and phases. One 
framework for dissociating the different reward components was proposed by Berridge and 
colleagues. They proposed that the major components of reward are (i)‘liking’, referring to 
hedonic impact and subjective pleasure of a reward; (ii) ‘wanting’, incentive salience, or 
motivation to approach a reward; and (iii) learning, the predictive associations and cognitions 
relating to reward (see e.g. Berridge, 2003, 2009). Other researchers have investigated reward 
events in terms of separate temporal phases, by decomposing the reward event into (i) 
anticipation/prediction and (ii) outcome/consummation (Knutson, Fong, Adams, Varner, & 
Hommer, 2001b). These two ways of parsing reward represent different perspectives on the 
reward process, but ultimately try to explain the same underlying idea.  The two temporal 
phases can also be viewed in terms of the psychological components, as the anticipation 
phase is dominated by motivation to approach and the wanting of the reward, whereas the 
consummation of the reward itself is where the hedonic value (liking) is determined 
(Kringelbach, Stein, & van Hartevelt, 2012). Learning can occur throughout the cycle of 
reward based on integration of motivational and hedonic value aspects of rewarding 
experiences.   
Extensive research in both animals and humans has been conducted to understand the 
underlying neurophysiological mechanisms of the brain reward system. Accumulating 
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information from affective neuroscience has begun to reveal an interconnected brain circuitry 
involving several neurotransmitter systems. Further understanding of causal mechanisms and 
nuances of these systems and phases of reward processing is a major aim for current reward 
research. 
Reward circuitry in the brain 
A number of cortical and subcortical brain regions have been implicated in reward 
processes (see Figure 1). An influential early contribution to the field of affective 
neuroscience came from electrophysiology studies in the 1950s. Using intracranial 
electrodes, Olds and Milner (1954) found evidence that electrical stimulation in ‘lower areas 
of the brain’ caused rats to repeatedly self-stimulate for pleasure. Following these 
experiments, numerous animal studies using methods such as single-cell-recordings and 
intracranial stimulation combined with classical conditioning paradigms have identified 
dopaminergic neurons in the nucleus accumbens (NAc) and the ventral tegmental area (VTA) 
at the centre of this reward system (e.g. Kelley & Berridge, 2002; Schultz, 2000; R.A. Wise 
& Bozarth, 1985).  
 
 
 
 
 
 
 
 
 
 
 
The striatum, including the NAc in the ventral striatum (VS), and its projection sites 
are believed to be at the core of the brain reward network in both animals and humans 
(Berridge & Kringelbach, 2008; Haber & Knutson, 2010; Porcelli & Delgado, 2009). The VS 
receives inputs from the orbitofrontal cortex (OFC) and the anterior cingulate cortex (ACC) 
as well as midbrain dopamine (DA) neurons, and projects to the ventral pallidum (VP) and 
the VTA and substantia nigra (SN). The VTA and SN in turn project back to the prefrontal 
Figure'1.'Selected'brain'regions'associated'with'reward'processing'in'humans.'Adapted'from'
(Kenny,'2011).'
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cortex (PFC) and regions of the thalamus. In humans, the targets of VTA neurons in striatal 
and limbic regions have been studied using positron emission tomography (PET) and 
functional magnetic resonance imaging (fMRI) to investigate the involvement of these 
regions in anticipation and prediction of rewards (Martin-Soelch et al., 2001; Porcelli & 
Delgado, 2009). The ventral striatum has also been implicated in processing of both positive 
and negative outcomes, and in subsequent reward related decision making (Delgado, 2007; 
Delgado, Nystrom, Fissell, Noll, & Fiez, 2000).  
Neutrotransmitters of reward.  Many neurotransmitter systems have been 
implicated in reward processes including endocannabinoids, serotonin, DA and endogenous 
opioids (Kranz, Kasper, & Lanzenberger, 2010; Laurent, Morse, & Balleine, 2015; Mahler, 
Smith, & Berridge, 2007; Schultz, 2002). DA has a central role in the traditional reward 
research, but there is now a growing body of evidence from animal and human studies 
supporting a key role for the µ-opioid receptor system in several aspects of reward 
processing.  
Dopamine.  Dopamine is the most widely studied neurotransmitter in reward 
research, and has been implicated in both motivation and reward learning (Berridge & 
Robinson, 1998; Björklund & Dunnett, 2007b; Schultz, 2007a, 2007b). A large distribution 
of DA neurons are located within the regions implicated in reward processing (illustrated in 
Figure 1), forming central DA pathways such as the mesostriatal, mesocortical and 
mesolimbic pathways (Björklund & Dunnett, 2007a).  
The mesolimbic DA pathway, consisting of dopaminergic neurons projecting from the 
VTA to the NAc, is consistently implicated in the processing of both natural and drug-
induced rewards in non-human animals (Kelley & Berridge, 2002; Nestler, 2005). Both types 
of reward are associated with an increase in extracellular DA in mesolimbic areas (Di Chiara 
& Imperato, 1988; Schultz, 2000). Self-administration is an established method used for 
studying the reinforcing effects of drugs, and animals will consistently self-administer a 
range of drugs that are commonly abused in humans (Koob, 1992). Changes in the 
mesolimbic DA system affect the motivation to work for rewarding drug stimuli. An early 
animal study showed that lesions in the NAc or VTA (resulting in reduced DA firing) were 
associated with decreases in self-administered cocaine in rodents (Roberts, Corcoran, & 
Fibiger, 1977; Roberts & Koob, 1982). More recent research has shown that mice lacking the 
most common DA receptor in the central nervous system (D1 ‘knock out’ mice) do not self-
administer cocaine at all (Caine et al., 2007; Thomsen, Hall, Uhl, & Caine, 2009). DA 
antagonists have been found to influence self-administration of MDMA (Brennan, Carati, 
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Lea, Fitzmaurice, & Schenk, 2009) and methylphenidate (Botly, Burton, Rizos, & Fletcher, 
2008) in rats.  
DA has also been implicated in reinforcement learning and is involved in coding of 
prediction errors depending on the size and value of rewards (Roesch, Calu, & Schoenbaum, 
2007; Schultz, 2007a). Prediction errors refer to a mismatch between predicted and actual 
event outcome, and are important for learning based on experience (Salamone & Correa, 
2012). DA neurons fire in response to salient stimuli. When an association is learned between 
a cue and a subsequent rewarding stimulus, the (phasic) burst of DA is transferred to the cue 
instead of the reward delivery (Schultz, 2007a). Once learned, the absence of a reward leads 
to a negative prediction error and stops the dopamine firing to a rewarding stimulus.  
Electrophysiological studies in rodents and non-human primates have demonstrated this 
conditioning in single DA neurons, providing a neural basis for cellular learning believed to 
underlie neurophysiological mechanisms such as long-term depression and long-term 
potentiation (Schultz, 2007b, 2010). In all, animal research supports a key role for DA in 
initial encoding of rewarding stimuli. In humans, DA-dependent prediction errors have been 
shown to underpin reward seeking behaviour (Pessiglione, Seymour, Flandin, Dolan, & Frith, 
2006). Increased DA activity in OFC, PFC and ACC has also been observed during 
engagement in reward tasks in humans, corroborating DA-involvement in reinforcement 
learning across species (Vrieze et al., 2013). 
In human clinical populations, imbalances in the DA systems are associated with 
disruptions in reinforcement learning and motivation. DA dysfunction has been implicated in 
the aetiology of ADHD, which is characterised by a range of learning and motivational 
deficits (Sagvolden, Johansen, Aase, & Russell, 2005; Volkow et al., 2012b). The primary 
treatment for ADHD is methylphenidate, a DA agonist that has been shown to increase 
available DA specifically in the VS and cause increased motivation, task engagement, and 
enhanced salience of stimuli (Groom et al., 2010; Volkow et al., 2001; Volkow et al., 2012b). 
The DA system is also implicated in the development of substance abuse. For example, 
studies have shown reduced reward sensitivity and reduced reward related activity in the 
mesolimbic DA pathway in substance dependent populations (e.g. Koob & Le Moal, 2001; 
Martin-Soelch et al., 2001; Volkow, Fowler, & Wang, 2002).  
Although evidence supports the involvement of DA in several reward-related 
processes, the exact role of DA in reward has been debated (e.g. Berridge, 2007; Koob, 1996; 
Volkow, Fowler, Wang, & Goldstein, 2002; R.A. Wise, 1980; R.A. Wise, 1982). Some 
research suggests that DA is essential for all aspects of reward, including hedonic liking of 
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rewarding stimuli (Koob, 1996; R.A. Wise, 1982). This idea has been challenged. For 
example, within Kent Berridge and colleagues’ reward component framework, DA has a 
primary role in ‘wanting’, through mediation of incentive salience mechanisms (Berridge, 
2007; Berridge & Robinson, 1998). This notion is consistent with the incentive sensitisation 
theory of drug addiction proposed by the same authors (Robinson & Berridge, 1993, 2008). 
The incentive sensitisation theory posits that repeated drug use changes the incentive salience 
associated with taking drugs, subsequently increasing ‘wanting’ of the drug to a 
disproportional level (Berridge, Robinson, & Aldridge, 2009).  
Together, evidence from animal research and studies on different clinical populations 
show the important role of DA in reward processing. Processing of both primary rewards and 
drug rewards is modulated by changes in DA activity, and regions in the mesolimbic DA 
pathway have been implicated in reward system deficiencies in many substance dependent 
populations (Daglish & Nutt, 2003; Nestler, 2005; Volkow, Wang, Fowler, & Tomasi, 
2012a). However, there is evidence that DA is not solely responsible for all aspects of 
reward, and accumulating evidence suggests that dopaminergic neurotransmission is not 
necessary for hedonic liking or pleasure per se (Berridge & Kringelbach, 2015). Recent 
research has also questioned the causal role of DA in motivation and approach behaviour, and 
argued for a more interconnected network involving other neurotransmitter systems also in 
this aspect of reward (e.g. Laurent et al., 2015).  
µ-opioid receptor system. In addition to being central in dopaminergic pathways, 
mesolimbic brain areas are rich in µ-opioid receptors (Mansour, Khachaturian, Lewis, Akil, 
& Watson, 1988). µ-opioid neurotransmission, particularly in the VTA-NAc pathway, has 
been shown to modulate multiple aspects of reward experience and behaviour (Nestler, 2005; 
Peciña, Smith, & Berridge, 2006; Wassum, Ostlund, Maidment, & Balleine, 2009). Opioids 
are essential in hedonic experience, or ‘liking’, of natural rewards such as high caloric food 
(Barbano & Cador, 2007; Leknes & Tracey, 2008; Nathan & Bullmore, 2009; Peciña & 
Berridge, 2000), the euphoric effects of drugs (Kreek, LaForge, & Butelman, 2002; Levran, 
Yuferov, & Kreek, 2012; Volkow, Fowler, & Wang, 2004), and social rewards and 
attachment (Burkett, Spiegel, Inoue, Murphy, & Young, 2011; Trezza, Damsteegt, 
Achterberg, & Vanderschuren, 2011) across species. Opioid agonist drugs increase dopamine 
release through inhibition of GABA (γ-Aminobutyric acid) inter-neurons, but also act 
directly on opioid receptors on NAc neurons (Johnson & North, 1992). Some evidence 
suggests that the rewarding effects of opioid drugs are independent of dopamine release 
(Daglish et al., 2008). Hnasko, Sotak, and Palmiter (2005) demonstrated intact opioid 
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agonist-induced reward in dopamine deficient mice. Similarly, a human PET study by 
Watson et al. (2013) found no detectable increase in striatal DA levels to either heroin reward 
or the expectation of heroin in a sample of opioid dependent patients.  
 Areas of the brain where µ-opioid receptor stimulation/agonism significantly 
increases the hedonic valuation of sweet taste rewards have been identified as hedonic ‘hot 
spots’ (Peciña et al., 2006). Two such ‘hot spots’ are found in the NAc and the VP (Peciña et 
al., 2006). In addition, there is evidence that opioid activation influences motivational impact 
and incentive salience of rewards in animals. In a study by Mahler and Berridge (2012), µ-
opioid stimulation of the central amygdala enhanced incentive salience of both learned and 
unlearned incentive stimuli in rats. Microdialysis studies have shown a surge in endogenous 
opioids (enkephalin) in the striatum during consumption of palatable foods in rodents 
(DiFeliceantonio, Mabrouk, Kennedy, & Berridge, 2012). Interestingly, the same study 
demonstrated that microinjections of a µ-opioid receptor agonist in the same area led to a 
250% increase in chocolate intake. This provides convincing evidence of opioid involvement 
in the ‘wanting’ of rewards. In a series of experiments, Wassum et al. (2009) found distinct 
neural circuits related to changes in hedonic impact and incentive salience of rewards in 
rodents. While opioid antagonists infused into the NAc or VP decreased sucrose palatability, 
the incentive salience of sweet rewards was affected only after infusions into the amygdala 
(Wassum et al., 2009). In addition, the opioid receptor system has been implicated in the 
integration of reinforcement values with instrumental learning to guide decision-making 
(Laurent et al., 2015). These studies support the role of opioids in several aspects of reward 
processing in animals. There is also evidence suggesting separable roles of the µ-opioid 
receptor system in different brain regions, which reflects a complex brain system responsible 
for coding and processing of rewarding stimuli.  
Some of the evidence from animal studies implicating opioids in reward processes has 
been extended to human research. Naltrexone, a non-selective opioid receptor antagonist, has 
been shown to reduce food intake and subjective appetite (Yeomans & Gray, 1997), and 
decrease the rewarding effects of sugar in several clinical populations (Laaksonen, Lahti, 
Sinclair, Heinälä, & Alho, 2011; Langleben, Busch, O'Brien, & Elman, 2011). Antagonism 
specifically at the µ-opioid receptor has been shown to decrease intake as well as hedonic 
liking of high-value food (typically sweet or fatty) in both animals (Parker, Maier, Rennie, & 
Crebolder, 1992; Taha et al., 2006) and humans (Nathan et al., 2012; Ziauddeen et al., 2013). 
Opioid antagonism also affects value-based decision making, as evidenced, for instance, by a 
study that demonstrated reduced preference for immediate (small) rewards over delayed 
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(larger) rewards (delay discounting) following naltrexone administration (Boettiger, Kelley, 
Mitchell, D'Esposito, & Fields, 2009). In addition, a study found that naltrexone 
administration reduced the reinforcing effects of amphetamine in healthy volunteers 
(Jayaram-Lindström, Wennberg, Hurd, & Franck, 2004). This shows interactions between 
DA and opioid systems in drug rewards in humans, consistent with findings of such 
interactions in animals (Johnson & North, 1992; Spreckelmeyer et al., 2011; Vindenes et al., 
2009).  
A small amount of psychopharmacology studies using opioid receptor agonism in 
healthy humans have shown reduced fear recognition sensitivity (Ipser et al., 2013), increased 
pleasantness ratings of neutral emotional images (Gospic et al., 2008), and increased 
attractiveness ratings and motivation to view beautiful faces (Chelnokova et al., 2014).  
Further research is needed to understand the mechanisms through which DA and 
opioid systems interact, and how the NAc-VTA pathway is implicated in the different 
components and phases of human reward processing.   
Neuroimaging studies of reward 
Blood-oxygen-level-dependent (BOLD) fMRI studies in humans have investigated 
different aspects of reward processing, including anticipation and prediction of reward, 
delivery/consummation of rewards and punishment, and rewards of different valence and 
magnitude. Although fMRI does not provide the best temporal resolution, it can be used to 
identify brain areas involved in cognitive and affective processes. fMRI does not measure 
neuronal activity per se, but the BOLD signal is considered to reflect energy usage and 
therefore approximate neural activity (Logothetis, 2002).  
The regions identified in animal studies as part of the reward circuit, such as the OFC 
and PFC, striatum, and the amygdala, are commonly activated in human fMRI studies on 
reward (Porcelli & Delgado, 2009).  Liu et al. (2007) used a reward decision-making task and 
found activation in the striatum and medial PFC during positive reward anticipation and 
outcome, whereas negative events (punishments) activated the lateral OFC, anterior insula, 
superior temporal pole and dorso medial frontal cortex (dmFC). A more recent meta-analysis 
revealed that the NAc was commonly activated during both positive and negative events 
across all stages of reward processing, while other areas were preferentially activated either 
to rewards (medial OFC and posterior cingulate cortex (PCC)) or punishments (ACC, 
anterior insula and lateral PFC) (Liu, Hairston, Schrier, & Fan, 2011). These studies illustrate 
that it can be valuable to separate anticipation and outcome stages of reward, and to study 
both rewards and punishment in fMRI paradigms.  
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To study sub-components of human reward processes, Knutson, Westdorp, Kaiser, 
and Hommer (2000) designed an fMRI task intended for parsing brain activity during 
anticipation and delivery of rewards. The Monetary Incentive Delay (MID) task is a simple 
reaction time task. A typical trial consists of a cue signalling either the opportunity to win or 
avoid losing a given amount of money (see Figure 2). Following a short delay, the target 
appears and the participant has to quickly press a button. Feedback is then presented on the 
screen stating whether the participant was successful (‘reward’ or ‘save’), or unsuccessful 
(‘miss’ or ‘loss’) depending on their accuracy (responding quickly enough to the target) and 
the type of trial. In the MID task, the reward is delivered or withheld based on the operant 
action (pressing the button) performed by the participant. 
   
 
 
 
 
 
 
 
 
 
 
 
The MID task has been used in many studies to investigate brain activity during 
reward prediction and outcome in both healthy and patient populations.  Striatal activation 
associated with anticipation and delivery of rewards in the MID task also correlates with 
other reward measures such as reward sensitivity (Santesso et al., 2008) and anhedonia scores 
(Wacker, Dillon, & Pizzagalli, 2009). In the original study by Knutson et al. (2000) and in 
many following studies (e.g. Furukawa et al., 2014; Knutson, Adams, Fong, & Hommer, 
2001a; Kumar et al., 2014; Pizzagalli et al., 2009; Rademacher et al., 2010; Wrase et al., 
2007), activation in NAc was observed in healthy individuals during anticipation of monetary 
gain. In addition, Knutson et al. (2001a) showed that activity in the NAc during reward 
anticipation was correlated with self-reported happiness. While initial reports indicated that 
the NAc was exclusively activated by anticipation of gain only (Knutson et al., 2001a; 
Knutson et al., 2001b), many later studies show NAc and other striatal activation during 
Figure'2.'Illustration'of'a'typical'trial'in'the'monetary'incentive'delay'(MID)'task.'Values'
in'the'outcome'stage'represent'task'earnings'for'the'trial'(top)'and'total'in'the'task'
(bottom)'in'US'dollar.'Figure'from'Knutson'et'al.'(2003).'
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anticipation of both gain and loss as well as during delivery of reward (Bjork, Smith, & 
Hommer, 2008b; Bustamante et al., 2014; Nestor, Hester, & Garavan, 2010; Scheres, 
Milham, Knutson, & Castellanos, 2007; Wrase et al., 2007). Some of the variation in results 
may be due to insufficient temporal separation of the reward event stages to accurately 
dissociate activity related to each stage separably in early versions of the MID task (Bjork et 
al., 2008b; Dillon et al., 2008). This issue has been addressed in more recent implementations 
of the paradigm. 
The MID task has also been used to investigate reward related brain activity after 
pharmacological interventions. In healthy populations, DA agonism has been associated with 
increased NAc activity to anticipation of rewards (Knutson et al., 2004; Ye, Hammer, 
Camara, & Münte, 2011) while reductions in available DA have been associated with 
decreased activation to reward anticipation (da Silva Alves et al., 2011; Saji et al., 2013). In 
clinical populations, the MID task has been used to study brain reward during treatment with 
drugs acting on neurotransmitter systems implicated in reward, such as neuroleptics (Juckel 
et al., 2006; Schlagenhauf et al., 2008), selective serotonin reuptake inhibitors (SSRI’s) (Stoy 
et al., 2012), and D9-tetrahydrocannabinol (THC) (Jansma et al., 2013; van Hell et al., 2012).  
Together, the studies presented above show that BOLD signal changes during the 
MID task are sensitive to pharmacological manipulations of systems known to be involved in 
reward processing. However, it is important to note that reward activation in the MID task is 
not always consistent across studies and populations. One study found a reduced VS response 
to anticipation of rewards in healthy controls but not in substance dependent individuals 
following a single dose of a DA agonist (Schouw et al., 2013).   
Despite some inconsistencies in reported results, the ability to disentangle brain 
activity to anticipation and outcome stages of reward renders the MID task useful for 
studying pharmacological effects on different facets of reward processing. To our knowledge, 
no previous studies have investigated the effect of opioid manipulation on different aspects of 
reward separately, such as anticipation and outcome. 
Neuroimaging with opioid receptor drugs.  While animal studies have the 
advantage of more extensive experimental control and the use of methods such as 
microinjections directly into opioid receptors, human research has to rely on more inferential 
methods to study the role of the opioid system. In recent years, advances in neuroimaging 
with methods such as pharmacological MRI are promising for studying drug effects on 
human brain processes by measuring drug related changes in BOLD signal (Colasanti, 
Lingford-Hughes, & Nutt, 2013).  
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The endogenous opioid system is heavily implicated in pain regulation, and µ-opioid 
receptor agonists are widely prescribed for pain relief due to their analgesic effects (Eidson & 
Murphy, 2013; Leknes & Tracey, 2008; Zubieta et al., 2001). The majority of fMRI studies 
using systemic opioid receptor manipulation in healthy volunteers come from the domain of 
pain and analgesia research. Opioid agonists such as morphine and remifentanil have been 
associated with increased resting-state BOLD activation in reward related regions such as 
NAc, amygdala, OFC, hippocampus, ACC, and insula during and following drug 
administration (Becerra, Harter, Gonzalez, & Borsook, 2006; Leppä et al., 2006). 
Wanigasekera et al. (2012) found that activity in the OFC, NAc and VTA also predicted 
analgesic effects of remifentanil in healthy volunteers. Furthermore, opioid agonists have 
been associated with a dose-dependent modulation of pain-induced BOLD response in limbic 
regions and reduced activation to pain in the insula and ACC (Upadhyay et al., 2012; R.G. 
Wise et al., 2002). A study by Atlas et al. (2012) corroborated these results by showing that 
reduction in pain related activation was independent of expectancy effects. A resting state 
fMRI study of healthy volunteers found reduced functional connectivity between the ACC 
and insula, and the ACC and putamen, after administration of the opioid agonist oxycodone 
(Gorka, Fitzgerald, de Wit, Angstadt, & Phan, 2014). The authors suggested that this could 
be a possible mechanism for the analgesic effects of opioids, by impairing both perception 
and appraisal of internal pain states (Gorka et al., 2014).  
Opioid antagonists, such as naloxone or naltrexone, are used more frequently in fMRI 
studies with healthy volunteers than agonists. In a pain simulation study by Borras et al. 
(2004), naloxone induced increased pain intensity ratings and BOLD response to pain in 
cortical and subcortical regions in the reward circuit, including NAc and OFC. In another 
study, naloxone infusion enhanced fear acquisition and was associated with sustained 
amygdala response to fear, while the amygdala response to the conditioned stimulus was 
decaying rapidly in the placebo condition (Eippert, Bingel, Schoell, Yacubian, & Büchel, 
2008).  
Opioid antagonism has also been associated with decreased activation to rewarding 
food images in the amygdala, ACC and caudate (Murray et al., 2014; Rabiner et al., 2011). 
Murray et al. (2014) found that naltrexone increased activation in the amygdala and insula in 
response to aversive food stimuli. Using a gambling task, Petrovic et al. (2008) showed that 
naloxone attenuated neural response to rewards of increasing magnitude in the ACC while 
increasing neural activity to losses of all magnitudes in the insula and caudal ACC. These 
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findings are consistent with the idea that endogenous opioid release attenuates the negative 
aspects of losses (Colasanti et al., 2013).   
Very few imaging studies have investigated the effects of µ-opioid receptor agonists 
on affective measures in healthy volunteers, likely due to high abuse potential of this type of 
drugs. In one recent fMRI study, BOLD response to emotional stimuli was measured 
following acute oxycodone administration in healthy volunteers (Wardle et al., 2014). 
Contrary to the hypotheses, oxycodone did not alter emotional processing in the primary 
regions of interest NAc and amygdala (Wardle et al., 2014). Notably, the study did not 
replicate drug-related effects in regions that have previously been associated with increased 
activity during resting state fMRI following opioid-receptor agonism (Becerra et al., 2006; 
Leppä et al., 2006). This highlights the need for further research into the effects of opioid 
receptor agonists on brain processes in the absence of pain.  
The current study 
To address central questions concerning opioid system involvement in reward in the 
healthy human brain, we designed a pharmacological fMRI study. Pharmacological fMRI 
requires a range of considerations that regular task-fMRI do not, and thus the current thesis 
has focused on preparing appropriate study procedures. To date, opioid agonists have 
primarily been used in fMRI studies of pain, analgesia, and drug addiction treatment. Opioid 
receptor agonists are widely used for pain relief (Vindenes, Handal, Ripel, Boix, & Mørland, 
2006), yet little is known about how opioids influence processes in the healthy human brain 
(Fields, 2007). Administering opioids to healthy, non-addicted, pain-free individuals has been 
approached with apprehension, partly due to abuse potential and methodological concerns. 
Notably, in healthy individuals, moderate doses of  ‘slow-acting’ µ-opioid receptor agonists 
produce very few subjective effects (Chelnokova et al., 2014; Hanks, O'Neill, Simpson, & 
Wesnes, 1995; O'Neill et al., 2000; Zacny & Lichtor, 2008).  
Combining pharmacological manipulations with fMRI has the potential to elucidate 
mechanisms involved in reward processing in healthy humans in a non-invasive matter 
(Iannetti & Wise, 2007; Knutson & Gibbs, 2007; Nathan, Phan, Harmer, Mehta, & Bullmore, 
2014). However, studies using this method are often limited by small sample sizes and lack 
of appropriate control measures (Becerra et al., 2006; Leppä et al., 2006; Wardle et al., 2014). 
Aims and hypotheses.  To gain further understanding of the involvement of the 
opioid system in anticipation and delivery of rewards, we used a previously validated 
paradigm to probe activity in relevant mesolimbic brain areas. Pharmacological fMRI was 
deemed an appropriate method to investigate functional differences in brain activity 
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following µ-opioid receptor manipulation. By developing appropriate control tasks and 
measures, this pilot study will precede a larger pharmacological study aimed at studying µ-
opioid receptor mechanisms in healthy volunteers. We decided to use the MID task (Knutson 
et al., 2001a; Knutson et al., 2000) to assess neural activity in response to monetary rewards 
and punishments in healthy individuals receiving a µ-opioid receptor agonist (morphine, 
10mg per oral) and placebo in two separate sessions. For this purpose, we designed a 
modified version of the MID task enabling analysis of brain activity associated with both 
anticipation and outcome of reward as well as punishment. We used (BOLD) fMRI signal 
changes in the brain to approximate neural activity in response to task stimuli. The aims of 
this thesis were to develop a study procedure to measure brain reward processes and potential 
pharmacological effects on these. To achieve the goal, this pilot study was planned to (1) 
choose, develop and validate a reward task suitable for measuring reward related brain 
activity, (2) test whether a µ-opioid receptor agonist, morphine, would increase reward 
related brain activity compared to placebo, and (3) find appropriate control measures for 
confounding pharmacological effects.  
We hypothesised that: 
1. Participants would show activation in the ventral striatum (specifically NAc) 
during anticipation and delivery of monetary gains.  
2. The activation in reward-related regions would be higher after administration 
of a selective µ-opioid receptor agonist, morphine, compared to the placebo 
condition, particularly during reward outcome (liking).  
Support for these hypotheses would validate the current task procedures for the main 
study of opioid effects on reward and motivation, and provide support for the involvement of 
opioids in reward processing in the healthy human brain.  
Methods 
Participants 
14 healthy volunteers were recruited for the current study from the University of Oslo 
and via acquaintances. Two participants were only tested once due to breakdown of the 
scanner head coil causing a delay in data collection. Two participants experienced aversive 
side effects. One participant felt discomfort during fMRI in the placebo condition and 
withdrew prior to the second session. Another participant felt nauseous in the morphine 
condition, but is included in the study sample since the aversive effects did not occur until 
after completion of the study tasks. This resulted in a final sample of 11 participants (4 
females, age range 21-33 years, M±SD= 26±3 years). All participants received written 
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information by email and underwent a medical screening per phone prior to testing. Grounds 
for exclusion were: contraindications to morphine, current prescription of opioids, 
antidepressant, or antipsychotic medications, current medical or neurological illness, history 
of alcohol or substance abuse, claustrophobia, and other contraindications to MRI such as 
metal implants or pacemaker. All participants were morphine-naïve (defined as no morphine 
in the last 2 years, as per Becerra et al. (2006)), right handed, and had normal or corrected to 
normal vision. Each participant underwent two separate testing sessions of approximately 3 
hours separated by a minimum of 1 day to avoid drug carry-over effects. Of the four female 
participants, two used hormonal contraception. The other two were unsure about timing since 
last menstruation and we were thus unable to assess phase of cycle. We tried to complete 
both test sessions within one hormonal phase by testing twice within a short time interval. In 
each session the participants received either morphine (10 mg per oral) or placebo prior to 
performing the tasks. Participants received a total monetary compensation of ~500 NOK 
(Norwegian Kroner), which included total earnings from the MID tasks (M±SD=184±16 
NOK). Before testing commenced, all participants provided written informed consent and the 
study was approved by the Regional Health and Ethics Committee (REK: 2011/1337/ Helse 
Sør-Øst).  
Design 
This study was conducted in a double-blind, placebo-controlled, counter-balanced 
manner with repeated-measures within subjects. The MID task was administered as part of a 
battery of reward tasks. Participants also completed a food wanting regulation task, an 
emotion recognition task, and selected trait and state questionnaires. Only results from the 
MID task and relevant control measures are reported in this thesis. Participants answered 
questions about mood and “subjective state” at three different time points during each session 
(see Figure 3). fMRI data collection commenced ~60 minutes after drug administration to 
coincide with stable and high plasma concentrations. Trait questionnaires were completed 
prior to drug administration to avoid potential influence of opioids on test answers.  
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Drug administration 
Morphine is a selective µ-opioid receptor agonist, and is a widely prescribed analgesic 
for acute pain (Eidson & Murphy, 2013). In the current study we used pills of 10mg 
morphine (Morfin®, Nycomed Pharma). This dosage was chosen to activate µ-opioid 
receptors without causing sedation or euphoria, and to limit subjective effects that could 
influence task behaviour (Chelnokova et al., 2014; Walker & Zacny, 1998; Zacny & Lichtor, 
2008). We chose oral administration, as it is less invasive for the participants than 
intravenous drugs. Orally ingested morphine reaches maximal effect 1-2 hours after intake 
and has a half-life of 2-4 hours (Lugo & Kern, 2002). Per oral morphine bioavailability is on 
average 20-30% but varies substantially between individuals (Hoskin et al., 1989). 
Placebo pills were cherry-flavoured breath mints chosen to visually resemble morphine pills. 
To avoid recognition by flavour, a small amount of the placebo pills were added to the 
morphine drug dose. To ensure successful blinding of participants and experimenter, the 
participants were instructed not to chew or visually inspect the pills (presented in a small 
black cup).  
Time line.  Participants provided 
written consent, and then completed a state-
relevant questionnaire. Following drug 
administration, participants waited for 60 
minutes before testing commenced. The 60-
minute delay was chosen in a previous study to 
allow for stable and high morphine 
concentrations (see Figure 4; Chelnokova et 
al., 2014; Eikemo, 2011). During the delay, 
participants watched a nature documentary for 
30 minutes before completing practice runs for 
the reward tasks. ~50 minutes after drug 
administration, participants completed the 
subjective effects questionnaire again inside the scanner prior to the tasks. After the imaging 
session (~110 minutes post-drug administration), participants provided a blood sample, and 
completed the remaining questionnaires, reward tasks, and a motor-coordination test 
(Giovannoni, Van Schalkwyk, Fritz, & Lees, 1999).  
 
 
Figure'4.'Time'line'showing'blood'
concentration'of'morphine'as'a'function'of'
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current'study.'Reprinted'with'permission'from'
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Control measures 
Checkerboard paradigm.  Opioids can have a depressing effect on respiration, 
which in turn can cause increased overall BOLD signal (K. Pattinson, 2008; K.T. Pattinson, 
Rogers, Mayhew, Tracey, & Wise, 2007) and a decrease in relative stimulus-induced BOLD 
signal (Cohen, Ugurbil, & Kim, 2002). To ensure that any differences in activation between 
the morphine and the placebo conditions were not due to overall changes in BOLD signal 
caused by physiological effects, we included a control task in the scanner.   
The visual cortex, and the occipital cortex generally, is low in µ-opioid receptors 
(Baumgärtner et al., 2006; Colasanti et al., 2013). Potential differences in activations in these 
areas are therefore a viable indication of drug effects not caused by opioid receptor 
stimulation by itself. We used a blocked visual checkerboard paradigm consisting of 
alternating blocks of a 1 second flickering checkerboard stimulus followed by 20 seconds rest 
(crosshair presented in the middle of the screen) for 4 minutes. This basic paradigm was 
chosen to induce consistent activation in the visual cortex and enable direct comparison of 
stimulus-induced BOLD signal between the two drug conditions. Participants were instructed 
to keep their eyes on the screen and not to blink while the checkerboard was presented. The 
paradigm was presented using E-prime 2.0 Professional software.  
Physiological measures.  As a second measure of respiratory effects of morphine, 
pulse and respiration were recorded during the functional scans to assess potential 
physiological changes between drug conditions. Heart rate and respiration recordings were 
also intended for modelling of physiological changes in fMRI analysis, but this was not 
performed on the small sample in the current pilot study. Pulse was measured with a pulse-
oximeter on the left middle finger, and respiration was measured with a pneumatic belt 
strapped on the left side of the abdomen.  
Motor coordination task.  Previous studies have found that DA modulation can 
influence motor coordination, and measuring this effect is important for interpretation of drug 
effects on behavioural measures (Pizzagalli et al., 2008). Drugs acting on the µ-opioid 
receptor system can interact with the DA system and affect DA release (Johnson & North, 
1992; Nestler, 2005). The Bradykinesia Akinesia Incoordination test (BRAIN test; 
Giovannoni et al., 1999) was included as a control task in the current study to ensure that any 
differences observed in the reward tasks were not due to changes in motoric functioning 
caused by sedation or morphine effects on DA. The test is a computerised finger-tapping test 
used to objectively assess upper limb motor function.  
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To complete the task, the participant was instructed to use their dominant index finger 
to press the buttons ‘s’ and ‘ø’ (15 cm apart) alternately on a keyboard as fast and accurately 
as possible for 60 seconds. The task was administered directly in a browser window on a 
computer and required no further software (Giovanni & Noyce, 
https://predictpd.appspot.com/).  
The BRAIN test generates four main outcome variables; 1) kinesia score (KS): total 
number of alternating key strokes in 60 seconds, 2) akinesia time (AT): total amount of time 
that keys are pressed, 3) dysmetria score (DS): a weighted index of incorrectly pressed keys 
corrected for speed, and 4) incoordination score (IS): a measure of rhythmicity based on the 
variance of time intervals between key strokes. The main variable of interest for the current 
study was the dysmetria score, as it provides an overall performance measure while also 
taking into account speed-accuracy trade-off strategies.  
Questionnaires.  Previous studies have shown that opioids can affect subjective 
experiences and induce euphoria in healthy participants (Becerra et al., 2006; Walker & 
Zacny, 1998; Zacny & Lichtor, 2008). Although the morphine dose in the current study was 
chosen to limit such influences (Chelnokova et al., 2014), we wanted to control for subjective 
effects relating to the drug dose. Participants completed a questionnaire about mood, and 
somatic and subjective effects of opioid drugs (e.g. feeling good, dizziness, feeling ‘high’). 
The questionnaire was used in Chelnokova et al. (2014), and was based on scales developed 
previously (Walker & Zacny, 1998; Zacny & Lichtor, 2008). The scale included items about 
direct drug effects such as ‘Do you feel an effect of the pills?’, ‘How much do you 
like/dislike the effect?’ and ‘Would you take the pills again?’. Items were rated on a visual 
analogue scale (VAS) from “Not at all” to “Very much/Extremely”. The participants 
completed the questionnaire pre-drug administration and at two later time points (~50 and 
~120 minutes post-drug administration). At the second time point, the questionnaire was 
administered while the participant was inside the scanner, before fMRI acquisitions, to 
measure subjective effects as close as possible to the reward tasks and the time of peak 
morphine blood concentration. Questionnaires were presented using MATLAB outside the 
scanner and E-Prime Professional inside the scanner. Items and rating scales were identical in 
both versions of the questionnaire.  
Blood test.  Levels of neurochemical compounds, such as opioids, can be measured in 
small amounts of blood (Johnsen, Leknes, Wilson, & Lundanes, 2015). To measure levels of 
relevant neurotransmitters and their metabolites in our current sample of healthy volunteers, 
we collected a blood sample following the fMRI tasks. The sample was taken approximately 
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110 minutes after drug administration. We used a finger prick blood test, and collected 120µl 
from each participant at each session. Blood samples will be analysed using the methods 
developed by Johnsen et al. (2015). Uptake of oral morphine varies between individuals, and 
data from the blood test will provide individual measures of opioid levels that can be entered 
in the reward task analyses. The results from this analysis was not finalised at the time of this 
thesis.   
Monetary incentive delay task development 
The MID task uses monetary incentives as reinforcement, and relies on the ability of 
these incentives to possess a stable value and elicit reward related brain activity. A benefit of 
using a secondary reward (money) in this task is that it allows for the investigation of 
loss/punishment as well as winning. The MID task has been shown to reliably probe neural 
activity in brain regions associated with reward, such as the striatum and OFC, during reward 
anticipation and delivery of reward feedback (Beck et al., 2009; Knutson et al., 2001a; 
Knutson, Fong, Bennett, Adams, & Hommer, 2003), and is a validated and widely used 
method for studying reward processing.  
The test protocol developed in this study is intended for use in a larger 
pharmacological fMRI study and in a clinical study of heroin dependent patients. The MID 
task has low cognitive demand as it does not require participants to make decisions or learn 
complicated rules, and has therefore been the chosen task in many previous studies of 
substance abuse (see review by Balodis & Potenza, 2014). Another benefit of the task is that 
it is designed to have constant accuracy across participants (Knutson et al., 2001a), and is 
therefore not dependent on individual performance.  
A literature review made it clear that previous implementations of the MID task differ 
on a range of parameters. There were variations both in designs and analyses in terms of 
reward modality used, reward type and amount of cues and rewards, inter-stimulus intervals 
and inter-trial intervals, task length and jittering (variable time intervals between task events). 
One of the main aims of the current pilot study is to develop appropriate testing protocols for 
the larger study. Therefore, we considered a number of aspects before deciding on the 
parameters to be used in the current version of the MID task. These will be discussed in the 
following paragraphs before moving on to task development. An overview of previous 
versions of the task is presented in Table 1. 
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Table&1
Version Examples&of&articles No.&of&cues Reward&magnitude Win&trials Loss&trials Accuracy Jittering* Limitations Strengths Comments
1
Knutson,&Adams,&et&al.&2001&&
Beck&et&al.,&2009
Knutson&et&al.,&2004
Wrase&et&al.,&2007
Scheres&et&al.,&2007
7&(or&8&with&
two&$0&cues)
R&$&&0.20&,&1,&&5&&&&&&&&&
+&$&&0.20,&1,&&5
$&0
x x ≈&66% ISI:&2R2.5s Insufficient&jitter&to&
separate&anticipation&and&
outcome
Can&parametrically&
analyse&activity&to&
increasing&magnitude
Report&changes&due&to&increasing&amounts.
2
Bjork,Knutson& &Hommer,&2008 9 +&$0.20,&1,&5,&(unknown)&&&&&&&&&&&&&
R$&0.20,&1.5,&(unknown)&&&&&&&&&&&&&
$0
x x ≈&66% ISI:2R2.5s Insufficient&jitter&to&
separate&anticipation&and&
outcome
Variation&of&version&1&(Knutson&and&colleagues).
3
Dillon&et&al.,&2008
Pizzagalli&et&al.,&2009
Santesso&et&al.,&2008
Admon&et&al.,&2014
3 +&$&1.96R&2.34&(m=&2.15)&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&
R&$1.81R2.19&(m=2.0)
x x Fixed&rate&50%&
(actual&
responses&not&
relevant)
ISI:&3R7.5s,
4.4R8.9s.&&&&&&&
ITI:&3R12&s
Actual&responses&not&
relevant.&Low&success&
rate.&Cues&do&not&indicate&
magnitude&so&cannot&use&
parametric&analysis&for&
anticipation
Jittering&,&can&
separate&anticipation&
and&outcome
Separating&anticipation&and&outcome,&jittering&
and&predetermined&for&balanced&task.&No&
feedback&on&cumulative&earnings,&common&in&
other&versions&to&present&this&with&feedback.
4
Simon&et&al.,&2010 3 +&€&1,&0.20,&0 x R Fixed&rate&
(40/100&
reward)
ITI:&1R8s&
(M=3.5)
No&ISI&jitterR&problem&for&
separating&outcome&from&
anticipation.&Also&no&
separate&loss&trials,&lose&
when&no&response&given.&
Probabilistic&element&
in&task,&different&
from&most&other&
versions.
Target&presented&either&left&or&right,&press&
corresponding&button.&Probabilistic&task,&so&not&
all&correct&responses&give&reward.
5
Knutson,Fong,&et&al.,&&2001& 3 +$1,&&&&&&&&&&&&&&&&&&&&&&&&&&&
&$0&(response)&&&&&&&&&&&&&&&&&&&&&&&&&&&&
&$0&(no&response)
x R ≈&66% ISI:&2R2.5s Insifficient&jitter&to&
separate&anticipation&and&
outcome.&No&loss&trials
Variation&of&version&1,&but&no&loss&condition.&
Both&a&zeroRincentive&'response'&and&a&'noR
response'&cue&(inhibition&of&motor&response).&
6
Bjork,Smith& &Hommer,&2008 4 High,&low&reward&($5,&
$0.50)&&&&&&&&&&&
$5&loss&&&&&&&&&&&&&&&&&&&&
$0
x x ≈&66% ISIs&+&ITI:&&&&&&&&&&&&&
2,4,6&s
Less&lossRtrials&than&winR
trials
Added&jitter&between&
all&elements&in&each&
trial
Also&double&response&trials.
7
Nestor&et&al.,&2010 3 Win,&lose,&no&incentive x x Aimed&for&50%& ISI:&2R8&s,
ITI:&2R8s
Low&success&rate.&No&
magnitude&variation,&only&
one&level&of&win/loss.
Added&temporal&
jitter&ISI&and&ITI
8
Bustamente&et&a.,l&2013 5 +€&0.20,&3&&&&&&&&&&&&&&&&
R€&0.20,&3&&&&&&&&&&&&&&&&&&&&&&&&&
No&response&cue
x x ≈&75% ISI:&0.2R2.25s,&&&&&&&
ISI2:&2R4s,&&&&
ITI:&0.2R4s&
(random)
Jittered&ISIs&and&ITI&to&
separate&events.&Two&
level&each&valence.&
Two&levels&win/loss,&plus&nonRresponse&trial.&
Higher&predictabilidty&of&outcome&than&other&
versions.
9
Jia&et&al.,&2010 6 +$0,&1,&5&&&&&&&&&&&&&&&&&&&&&&&&&&
R$0,&1,&5
x x ≈&66% ISI:&3R5s,&
ISI2:&3R5s,&
ITI:&13sR(time&
of&trial)
Use&word&cues&to&
avoid&having&to&
remember&cue&
meanings
All&trials&same&length&(13s),&ITI&is&the&time&
"leftover"&after&other&task&events
10
Andrew&et&al.,&2011
Patel&et&al.,&2013
6 +$0,&1,&5&&&&&&&&&&&&&&&&&&&&&&&&
&R$0,&1,&5
x x ≈&66% ISI:&3R5s,&
ISI2:&3R5s,&
ITI:&13sR(time&
of&trial)
Separation&of&preR
target&and&postR
target&anticipation
Modified&from&version&1:&&separate&phase&1&
(anticipation&of&motor&response:before&target)&
from&phase&2&(anticipation&of&reward:&after&
target)
11
Kumar&et&al.,&&2014 2 +&(range&$0.95R1.15,&
m=$1.05)&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&
$0
x R ≈&66% ISI:&3,&4.5,&6,&&&&&&&&&
ISI2:&
2.8,4.3,5.8,&&&&&&&&&&&&&
ITI:&3,&4.5,&6
No&loss&trials.&Cue&not&
indicative&of&amount,&only&
valence
No&feedback&on&cumulative&earnings&during&
task,&common&in&other&versions&to&present&this&
with&feedback.
A&nonRexhaustive&selection&of&different&versions&of&the&MID&task&used&in&previous&literature.
"Notes:&Version&numbers&in&column&1&are&arbitrary&and&refer&to&different&versions&of&the&task&identified&by&the&author,&and&does&not&reflect&order&of&importance&or&when&it&was&published.&“x”&denotes&yes,&“R“&denotes&not&present&or&not&
reported.&*Jittering:&variable&time&intervals&between&task&events.&ISI=&interRstimulusRinterval,&ITI=interRtrialRinterval,&time&information&in&seconds&(s).
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Variation in MID task design.  
Trial types.  Many MID paradigms include cues signalling monetary gain and loss as 
well as neutral (no-incentive) cues (Knutson et al., 2000). However, results from both types 
of trials are not always discussed, and many studies do not report results from loss trials (e.g. 
Jia et al., 2011). Some studies do not include loss-trials at all, potentially influencing 
processing of the incentive trials as the participants become accustomed to receiving rewards 
(Balodis & Potenza, 2014). The studies that do report results from both types of trials have 
found inconsistent results. Some have found activation in the VS during both anticipation of 
winning money (win-trials) and anticipation of losing money (loss-trials) (Bjork et al., 2008b; 
Scheres et al., 2007; Wrase et al., 2007), while other studies find striatal activation in win-
trials only (Bjork, Knutson, & Hommer, 2008a; Knutson et al., 2003). Notably, few studies 
have directly contrasted anticipation of winning versus losing, a contrast that would allow for 
further dissociation of positive and negative incentive processing (Balodis & Potenza, 2014). 
Dissociating anticipation from outcome.  Previous studies vary the length and 
variability in time between anticipation and outcome phases in the MID task, and this affects 
the ability to analyse anticipation and outcome periods separately in the fMRI analysis. Bjork 
et al. (2008b) discussed the issue of insufficient variation in time between events in early 
versions of the MID task (e.g. Knutson et al., 2001a; Knutson et al., 2001b), and suggested 
adding variable delays (jitters) between task events (anticipation and outcome) to allow for 
separation during analysis. More recent studies have incorporated different variable delays 
into the task structure (e.g. Jia et al., 2011; Kumar et al., 2014; Pizzagalli et al., 2009). A 
consequence of this is that the definition of “anticipation period” also varies between task 
implementations. Some previous studies have defined anticipation as the delay between cue 
and target (Knutson et al., 2004; Knutson et al., 2001b; Knutson et al., 2003; Saji et al., 2013) 
while others define anticipation as only the actual cue presentation (Admon et al., 2014; 
Bjork et al., 2008b; Dillon et al., 2008; Kumar et al., 2014; Nestor et al., 2010; Pizzagalli et 
al., 2009; Simon et al., 2010). The latter method allows for separation of the two phases of 
reward in the analysis, but can measure anticipation activation only to the information of 
reward (cue) and not during the following delay.  
Accuracy.  Most MID paradigms use a practice run and a genetic algorithm to titrate 
task difficulty and obtain an accuracy rate of approximately 66%. Keeping a consistent 
success rate across participants has been found to maintain the motivation to respond and 
expectation of reward (Balodis & Potenza, 2014). 66% is based on the success rate required 
to keep DA neurons firing in monkeys while performing similar reward tasks (Fiorillo, 
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Tobler, & Schultz, 2003). In other versions of the task, the accuracy rate has been controlled 
using a predetermined schedule of successful and non-successful trials (Admon et al., 2014; 
Dillon et al., 2008; Pizzagalli et al., 2009; Santesso et al., 2008). In this alternative method 
the actual responses of the participants do not matter, but participants still believe that 
outcomes rely on their performance. Studies using this version have reported similar 
activation patterns as with the original design. 
Cue type.  MID paradigms also use different types of cues (words, symbols, colours) 
that can influence the working memory load required to remember the different meanings (Jia 
et al., 2011). The number of cues also varies. Some studies have only one magnitude of 
reward and/or loss (Knutson et al., 2001b; Nestor et al., 2010), while other studies vary the 
amount of money to be won or lost or divide trials into high reward and low reward (Beck et 
al., 2009; Knutson et al., 2001a; Knutson et al., 2004). In addition, some studies include a 
‘non response cue’ (instructing participants not to respond on the upcoming trial) as a 
measure of response inhibition (e.g. Scheres et al., 2007). As such, the number of cues and 
their meaning vary greatly between task implementations.  
Despite the variation in task design, previous studies using the MID task have 
consistently found activation in the brain regions relevant for rewards, such as the VS and 
OFC. The different versions of the MID task each enable a range of different hypotheses and 
analyses depending on the number of trials in each condition and magnitude of reward. In the 
current study we wanted to include anticipation of both winning and losing as well as 
delivery of both reward and punishment (loss), and analyse brain activation associated with 
each of these conditions. 
Task development. The MID script used in this study is adapted from a paradigm 
used in an ongoing multi-platform addiction study at several Universities in the United 
Kingdom (ICCAM Platform Study). This task version uses arrow symbols to indicate win or 
loss, as opposed to different geometric shapes (e.g. Knutson et al., 2004; Knutson et al., 
2003), colours (e.g. Nestor et al., 2010), or words (e.g. Andrews et al., 2011; Jia et al., 2011; 
Patel et al., 2013). We chose these symbols as they provide intuitive meaning to the cues 
(arrow up for potential win, arrow down for potential loss, see Figure 5) and therefore require 
less effort from the participants in terms of remembering meaning of cues. This was 
especially important since the task developed in this pilot study will be used in a clinical 
sample of heroin dependent individuals.   
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To allow for analysis of both win and loss trials, we included an equal number of 
trials for each incentive condition. We also included two levels of each incentive cue (win: 
high, low; loss: high, low) as well as neutral cues to allow for parametric analyses.  
 
 
 
 
 
 
 
 
 
 
Design and jittering.  One important consideration for the current pilot study was 
designing the MID task in a way that would make it possible to separate brain activity related 
to anticipation and outcome of reward. While Knutson et al. (2001a) and many following 
articles presented results from anticipatory periods only, other studies included both 
anticipation and outcome in their analyses. Pizzagalli et al. (2009) found that anhedonic 
patients with major depressive disorder did not significantly differ from controls in the 
anticipation of reward in the MID task, but they observed a difference in NAc and caudate 
activity to rewarding outcomes. This study, among others, shows that groups can differ in 
reward related activity in specific phases of reward processing.  
The MID task has been optimised for presentation in an event-related design, and the 
two phases of reward under investigation, anticipation and outcome, occur within a short 
period of time (Knutson et al., 2004). Event-related (rapid) fMRI is preferable to block 
designs if the intent is to isolate separate psychological events and maximise number of trials 
within a short period of time to avoid long and tedious tasks (Wager & Nichols, 2003). To 
separate brain activity associated with anticipation and outcome of reward, the MID task was 
modified from its original design. The original task by Knutson et al. (2000) did not include a 
contrast of outcome related activity, an addition that was implemented in Knutson et al. 
(2001b). More recent studies have concluded that the inter-stimulus intervals (ISIs) were too 
Figure'5."The"different"cues"signalling"win"trials"(A),"loss"trials"(B),"and"neutral"trials"(C)"with"the"
associated"magnitude"of"potential"win/loss."Values"in"NOK"(Norwegian"Kroner)."""
A B C 
+ kr 1 NOK 
- Kr 5 NOK + kr 5 NOK 
Kr 0 NOK - Kr 1 NOK  
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short and/or not sufficiently jittered (having varying durations) to successfully disentangle the 
associated activity from the two events in this version of the task (Bjork et al., 2008b). One of 
the primary challenges with using rapid event-related fMRI is that the BOLD signal follows 
the slow time course of the haemodynamic response in the brain, peaking at approximately 5-
8 seconds after a stimulus is presented (Kao, Temkit, & Wong, 2014; Logothetis, 2002; 
Serences, 2004). On the other hand, the psychological events we are making inferences about 
are often over in a few hundred milliseconds. The statistical power of effects in rapid event-
related designs relies heavily on the sequence of events and timing parameters and how these 
interact (Wager & Nichols, 2003). A solution for disentangling activity from separate 
conditions that require a rapid presentation rate is to add jitters between events within a trial 
(ISIs) and between different trials (ITIs; inter-trial-intervals). This means that the sampled 
time points for the events are distributed along the BOLD response curve, thus enabling 
deconvolution analysis (estimating the haemodynamic response function (HRF) for each 
event type separately) (Serences, 2004). Introducing sufficient jittering between events in the 
MID task will facilitate deconvolution analysis of anticipation and outcome separately 
(Dillon et al., 2008). Jittering in the MID task has been done in different ways in previous 
studies (Bjork et al., 2008b; Pizzagalli et al., 2009).  
When defining the anticipation and outcome periods in the MID task, a decision had 
to be made regarding how to dissociate these two phases of reward processing. To allow for 
separation of anticipation and outcome phases with jitters, we modelled only the presentation 
of the incentive cue as “anticipation” in the current study, (Bjork et al., 2008b; Dillon et al., 
2008). This means that anticipation refers to the neural response to cue presentation, and not 
the anticipation of a predicted reward that may last until the onset of target (during the delay). 
While this could be a limitation, previous studies have found anticipatory brain activation 
using this method before (e.g. Dillon et al., 2008; Kumar et al., 2014). Modelling anticipation 
as the whole period until target onset makes it difficult to separate brain activation to 
anticipation and outcome due to the lack of variable timing, and the benefit of being able to 
investigate the separate temporal phases of reward was considered to outweigh the potential 
limitations of this approach. In the following method description and analysis, anticipation 
will therefore refer to the presentation of the incentive cue (see Figure 6).  
To find the optimal length and distribution of jitters that would allow for efficient 
separation of anticipation and outcome, without making the task too long or too difficult, we 
used the FSL design tool (FMRIB Software Library, http://www.fmrib.ox.ac.uk/fsl). A 
selection of jitter schedules used in similar designs were tested for relative power using FSL 
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fMRI Expert Analysis Tool (FEAT) full model set up. We chose to use a reversed 
exponential distribution of the jitter lengths, with a higher frequency of the short jitters than 
the long. This was done to maximise variation in time between events without sacrificing 
number of trials or experiment duration (Serences, 2004). Different combinations of jitters 
were combined in a random order with task events (anticipation and outcome) using 
MATLAB 8.3 (R2014a, The MathWorks, Inc., Natick, Massachusetts, United States). The 
generated event files were then entered as a general linear model (GLM) in FEAT and the 
power of the relevant contrasts was compared across the different variations.  By comparing 
the correlation between predictors in each design, we estimated each predictor individually to 
get an approximation of the detection power of the full model (Wager & Nichols, 2003). 
Using this method, ISIs of 2,4, and 6 seconds, and ITIs of 1,3, and 5 seconds were chosen for 
the final task. This range of jitters gave the best estimated power to detect activation changes 
for both event types (anticipation and outcome), compared to the other jittering schedules 
tested (ISI/ITI: 2,4,6 seconds (Bjork et al., 2008b), ISI: 2,3,4 seconds, ITI: 3,4,5 seconds 
(ICCAM Platform study)). Figure 6 illustrates the distribution of jitters as well as the 
modelling of task events. 
 
 
 
 
 
 
 
 
 
 
 
 
Following from the test of jittering schedules, we decided to have 100 trials in the 
MID task. Each cue type occurred 20 times, resulting in 40 win trials and 40 loss trials 
(collapsed across magnitude) for each session. This was similar to previous task 
implementations (e.g Beck et al., 2009; Pizzagalli et al., 2008; Santesso et al., 2009). The task 
Figure'6.'Depiction"of"the"jittering"distributions"and"the"modelling"of"anticipation"and"
feedback"periods"within"the"MID"task"design."ISI="interIstimulusIinterval,"ITI="interItrialI
interval."Timing"information"in"seconds"and"milliseconds"(ms)."
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was split into two runs of equal length, each consisting of 50 trials. This would make it easier 
for participants to maintain concentration and remain still in the scanner throughout the task, 
and limit effects of fatigue. In the case of having to interrupt scanning due to unforeseen 
circumstances, each of the two runs could also be analysed separately. To obtain a balanced 
task with equal frequencies of trials evenly distributed throughout each run, we used a pre-
determined pseudo randomisation of cue type and jitter (Kao, Mandal, Lazar, & Stufken, 
2009). Choosing a pre-determined order of events has been shown to be preferable over a 
completely random stimulus presentation in event related experiments (Maus, Van 
Breukelen, Goebel, & Berger, 2010; Wager & Nichols, 2003). MATLAB was used to 
generate pseudo-randomised orders, with restrictions on the frequency of cues and proximity 
between cues of the same type. From a sample of 200 randomisations, the order with the 
most evenly distributed cues along the timeline (i.e. all cue types spaced out over the length 
of the task) was chosen and implemented in the final task design. This randomisation order 
was then reversed to make a second version of the experiment. 
Final task design.  The final task structure was decided based on the design 
considerations discussed. Each trial commenced with a cue signalling the possibility of 
winning (win trial; +1 or + 5 NOK), losing (loss trial; -1 or -5 NOK) or neither winning or 
losing money (neutral trial). Monetary values were based on previous studies using the task 
(Andrews et al., 2011; Jia et al., 2011; Simon et al., 2010). The cue was presented for 1 
second (s), followed by a jittered delay (ISI; 2s, 4s, or 6s). A target was then briefly presented 
(150-500 ms), during which the participants were expected to respond to the stimulus, and 
followed by an ISI (100-450 ms). Feedback presentation (1.5s) followed immediately after, 
consisting of trial accuracy (and money won or lost depending on trial type) as well as the 
accumulated earnings thus far. Feedback was followed by a jittered ITI (1s, 3s, or 5s) during 
which a crosshair was presented before the beginning of the next trial (see Figure 7). The task 
was presented in two runs of fifty trials (10 trials per each cue type) and each run lasted 
approximately 7 minutes separated by a break. 
Participants viewed the task stimuli on a projected screen (screen resolution 
1920x1080 pixels) through a mirror mounted on the head coil and responded to the task by 
pressing a button with their index finger on a response grip in their right hand. E-Prime 2.0 
Professional software (Psychology Software Tools, Pittsburgh, PA) was used to administer 
the task. 
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Prior to performing the MID task in the scanner, participants completed a practice run 
outside the scanner to ensure they understood the task completely and to collect mean 
response times (RTs). This participant’s mean RT from the practice run was used to titrate 
the duration of target presentation in the main experiment to ensure ~66% success rate. In 
both the practice run and the main experiment, an adaptive algorithm tracked the participant’s 
RTs and adjusted the allowable response window on a trial-by-trial basis to keep the task 
difficulty consistent. The response window was adjusted separately per valence condition to 
ensure similar accuracy across conditions.  
The participants were told that they would accumulate money during the task (not 
including the practice run), and would receive the total amount won at the end of the second 
test session. The starting amount was 50 NOK, and for each trial the corresponding sum was 
added or deducted.  
fMRI parameters 
Images were acquired using a 3.0-Tesla Philips Ingenia MRI scanner equipped with a 
32-channel SENSE head coil (Philips Medical Systems, Best, The Netherlands). High-
resolution T1 weighted images were acquired for anatomical reference and co-registration 
(voxel size 1 x 1 x 1mm, TR/TE 4.7/2.3, 184 slices, field of view (FOV) 256x184, 
overcontiguous sampling). For the MID task, each participant underwent two gradient echo, 
echo-planar-imaging (EPI) functional scans, each lasting approximately 7.5 minutes with 200 
Figure'7."Typical"trial"structure"for"a"win"trial."ISI="interIstimulusIinterval."ITI="interI
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volumes. For the checkerboard paradigm, 115 volumes were collected. The following 
parameters were used for all functional scans: 3 x 3 x 3mm voxels, TR= 2208 ms, TE= 30 
ms, flip angle 80°, FOV 240 x 126mm. Fourty-two transverse slices were collected (phase 
encoding direction from anterior to posterior) parallel to the anterior-posterior-commissure 
(AC-PC) axis. 
Slice acquisition.  The current study was one of the first fMRI studies to be 
conducted on a new Phillips Ingenia 3T scanner at The Intervention Centre at Oslo 
University Hospital. It was of interest both for the current and future studies to optimise the 
scanner settings to ensure the best possible data recording. To find the acquisition method 
that would maximise BOLD signal sensitivity, we performed a test comparing level of 
activation and temporal signal-to-noise ratio between different slice acquisition schemes. To 
evoke high activity in visual and motor cortex we used a visual flickering checkerboard 
paradigm combined with finger-tapping alternating on the right and left hand during the 
checkerboard periods. This allowed us to compare BOLD activation between the different 
acquisition schemes.  
Interleaved acquisition is more susceptible to spin history motion artifacts due to the 
temporal delays between acquisition of adjacent slices (Cheng & Puce, 2014). As the 
protocol designed for the current study will also be used in a clinical sample where head 
motion is a potential problem, we decided to focus mainly on sequential acquisitions in this 
test. The sequential acquisitions were collected in descending slice order.  
60 volumes were collected using each of four slice acquisitions: sequential with 0mm, 
0.3mm (10% of voxel size), and 0.5mm gaps, and interleaved acquisition (0mm gap). The 
other parameters were identical for the four scans: TR/TE = 2208/30, FOV 240 x 126, voxel 
size 3x3x3, 42 transverse slices. Data was acquired from a single subject during a blocked 
paradigm of 15s flickering checkerboards and 15 seconds rest. Each scan lasted 2 minutes, 
resulting in four checkerboard + finger-tap blocks per scan. The functional scans were pre 
processed using standard FSL FEAT settings. Based on visual inspection of the activation 
maps, it was decided to use sequential acquisition with 0.3 mm slice gap to maximise 
activation in frontal and subcortical regions. 0.5mm gap yielded a marginally larger Z-stat 
max score (Z= 15.9 versus 12.5), but the smaller gap was preferable in the absence of any 
larger differences.  
Parallel imaging.  Using parallel imaging (sensitivity encoding; SENSE) for 
functional scans has been shown to minimise susceptibility distortions and reduce influence 
of physiological noise, thus increasing spatial resolution as well as allowing data to be 
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collected in a shorter time period (Preibisch et al., 2003; Triantafyllou, Polimeni, & Wald, 
2011). There have been concerns about using a SENSE factor higher than 2 in the past due to 
reductions in signal-to-noise ratio (SNR), especially in brain areas where the BOLD signal is 
usually weak and susceptible to artifacts (Preibisch, Wallenhorst, Heidemann, Zanella, & 
Lanfermann, 2008; Schmidt, Degonda, Luechinger, Henke, & Boesiger, 2005). However, 
these conclusions have been drawn based on data collected with 8-channel head coils. A 
higher number of channels in the head coil has been shown to increase SNR and allow for 
higher SENSE factors without compromising the signal (Triantafyllou et al., 2011). Since the 
scanner used in the current study was equipped with a 32-channel head coil, a SENSE factor 
of 3 was chosen to maximise signal and minimise signal distortions and physiological noise.  
Analysis 
Control measures. 
MID task behavioural measures.  The MID task is designed to minimise variation in 
performance, and we therefore predicted no significant effects of session or drug order on 
accuracy (percent correct responses within the response window). Response times were 
controlled by the adaptive algorithm used to titrate accuracy, and therefore no analysis was 
performed on response time data. Average accuracy rates were analysed using a 2 x 5 
repeated measures analysis of variance (ANOVA) comparing drug (2: morphine, placebo) 
and cue type (5: positive valence (+5, +1 NOK), negative valence (-5, -1 NOK), and neutral). 
An ANOVA was also used to compare performance in the first and second session to ensure 
there were no learning effects. All statistics on behavioural data were analysed using 
Statistical Package for the Social Sciences (SPSS INC., Chicago, IL, USA). 
Motor coordination task.  To analyse the effect of drug on motor coordination, the 
results from the BRAIN test were entered as one-way repeated measures ANOVAs for each 
of the sub-scores (KS, AT, IS, DS) with drug (morphine, placebo) as the independent 
variable.   
Subjective effects.  To avoid potential false negatives due to correction for multiple 
comparisons, analysis of subjective effects was performed only on the three most relevant 
items ‘feeling drug effect’, ‘feeling high’, and ‘feeling good’ from the questionnaire. Paired t-
tests were used to analyse difference between baseline ratings (pre-drug) and the post-drug 
ratings between morphine and placebo conditions.  
Physiological measures.  To compare pulse and respiration patterns between the two 
drug conditions we set up a frequency spectrum analysis in MATLAB using fast Fourier 
transform. Reported respiration rate and pulse correspond to the frequency of the highest 
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amplitude harmonic obtained for each measure, and the analysis was based on physiological 
data recorded from the first run of the MID task during fMRI. One-way repeated measures 
ANOVAs were then performed to compare morphine and placebo conditions. Due to 
technical problems setting up the protocol, physiological data was only available for six 
participants. 
fMRI analysis.  fMRI data processing was carried out using FEAT (fMRI Expert 
Analysis Tool) version 6.00, part of FSL. Registration of functional data to individual high-
resolution and standard space images (Montreal Neurological Institute; MNI) was carried out 
using FLIRT (Jenkinson & Smith, 2001). Further pre-processing statistics included motion 
correction (Jenkinson, Bannister, Brady, & Smith, 2002), slice-timing correction using 
Fourier-space time-series phase-shifting, removal of non-brain tissue using BET (Smith, 
2002), spatial smoothing with a Gaussian kernel 5mm, grand-mean intensity normalisation, 
and high pass temporal filtering. Statistical analysis of the time-series was carried out using 
FILM with local autocorrelation correction (Woolrich, Ripley, Brady, & Smith, 2001). 
Cluster-based Z statistic images were thresholded at Z > 2.3, and clusters significant at the p< 
.05 level after correction for multiple comparisons are reported as significant activations.  
Checkerboard paradigm.  The checkerboard time series’ were analysed using a 
general linear model (GLM) design matrix with one explanatory variable (visual stimuli 1 
second), which was convolved with a double-gamma HRF. Fixed effects (FE) analysis for 
each drug condition was run to get the average activation maps per condition. The two drug 
conditions were also contrasted using another high level analysis with the contrasts morphine 
> placebo, and placebo > morphine. 
MID task.  MID task fMRI data was analysed as a GLM with the following 
explanatory variables (EVs) entered in the design matrix: 5 incentive cues, 5 successful and 5 
non-successful outcomes corresponding to cue, and 1 target (as well as the temporal 
derivatives of these EVs) convolved with a double-gamma HRF. In addition to the separate 
EVs, relevant contrasts entered in the first level analysis were: 1) anticipation of win versus 
neutral cue, 2) anticipation of loss versus neutral, and 3) successful outcome versus non-
successful outcome. The contrasts were selected to test whether this task version was 
successful at inducing activity in areas associated with human reward processing.  
Following first-level analysis using FEAT, the two runs for each person per session 
were combined using FE analysis to get a an average for each individual per drug condition. 
Relevant COPE images from these FEATs were entered in third-level FE analyses to get 
mean activation maps for each drug condition for each contrast of interest. Fixed effects 
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analysis was deemed appropriate due to the small sample size and preliminary nature of 
analyses in the current study. Finally, separate third-level repeated measures FE analyses 
were run contrasting the two drug conditions (contrasts: morphine > placebo, and placebo > 
morphine). 
ROI analysis. Following the whole brain analysis, FSL’s tool featquery was used to 
obtain mean signal change within a priori regions of interest (ROIs). We selected ROIs based 
on a recent unpublished ALE (activation likelihood estimation) meta-analysis of studies using 
the MID task (McGonigle, personal communication; ICCAM Platform Study). For the 
anticipation phase of the MID task, this review identified MNI weighted centre coordinates in 
the bilateral ventral putamen (right: 15, 9, -4, left: -15, 9, -6) and right insula (33, 23, -4). In 
the outcome stage, peak coordinates were identified in the bilateral NAc (right: 10, 18, -4, 
left: -12, 6, -10). To define ROIs for the current study we used these peak coordinates to 
create spheres of 6mm radius using FSLmaths, similar to the methods described in a previous 
MID task study (Cho et al., 2013). Upon visual inspection of these masks, it became clear 
that the left NAc and the left putamen masks were overlapping, and according to the Harvard 
Subcortical atlas (in FSL) this region corresponded better to the putamen than the NAc. 
Instead, we used the coordinates for the right NAc mask and created a new ROI for the left 
NAc based on these (-10, 18, -4). An illustration of the final ROIs can be seen in Figure 8.  
Figure'8."A"priori"region"of"interest"(ROI)"defined"masks"in"the"nucleus"accumbens"(NAc;"blue),"
ventral"putamen"(red),"and"right"insula"(light"blue)"in"coronal"and"sagittal"view."All"coordinates"
refer"to"MNI"(Montreal"Neurological"Institute)"standard"space,"and"masks"were"created"as"
6mm"spheres"around"the"peak"coordinates"identified"in"the"ICCAM"Platform"Study"metaI
analysis"(McGonigle,"personal"communication).""The"left"side"of"the"coronal"images"correspond"
to"the"right"side"of"the"brain.""
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Results 
Subjective effects and control data  
MID task behavioural results.  The average accuracy across participants and 
conditions was 65%, reflecting successful control of accuracy rate in the task design. To test 
whether the task titration ensured constant performance across conditions, a 2(drug) x 5(cue 
type) repeated measures ANOVA compared difference in performance between conditions. 
Because Mauchly’s test of sphericity was significant (p< 0.05) for all comparisons, results are 
reported using the Greenhouse-Geisser correction. There was a significant main effect of cue 
type (F(2.1, 21)= 10.17, p<.001, !!= .504), and pairwise comparisons (corrected for multiple 
comparisons using the Bonferroni correction) indicated that this was driven by the highest 
value positive cue being significantly different from the low value positive cue (p=.029) and 
the neutral cue (p=.019; see Figure 9). The main effect of cue was due to differences between 
magnitudes within one condition, thus yielding constant accuracy between valence conditions 
(as per task design). There were no significant effects of drug, drug*cue interaction, or 
session on accuracy (all F< .67, p>.43).  
 
 
 
 
Motor coordination task.  Four one-way repeated measures ANOVAs were used to 
compare motor functioning between drug conditions. Data from one participant was excluded 
due to computer errors. For the main variable of interest, dysmetria score, there was no 
significant effect of drug (F(1,9)=.27, p=.615, !!=.272). Neither were there differences 
between conditions on the other measures KS, AT and IS (all F< .81, p>.391).   
Figure'9."Accuracy"(%"correct"responses"inside"response"window)"across"all"cue"conditions""
(denoted"by"values"in"Norwegian"Kroner"(NOK))"in"the"monetary"incentive"delay"(MID)"task"
for"morphine"and"placebo."When"averaging"accuracy"rates"within"each"cue"valence,"
performance"was"constant"at"~65"%"for"all"conditions."Error"bars"represent"withinIsubjects"
standard"error"of"the"mean"(SEM).""
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Subjective effects.  When asked at the end of the second session to guess the drug 
conditions, participants only correctly identified if they received placebo or morphine 64% of 
the time. Paired t-tests showed no significant difference between baseline corrected session 
average subjective ratings of feeling drug effect (p= .91), feeling ‘high’ (p= .47), or feeling 
good (p= .89). Thus, any potential drug effects in the reward tasks cannot be attributed to 
subjective feelings of being under the influence of drugs.  
Physiological measures.  Despite having data from both drug conditions for only six 
participants, analysis showed a significant difference between drug conditions on respiration 
(F(1,5)=8.2, p=.035, !!=.622), but not heart rate (p= .435). On average, respiration rate was 
lower in the morphine condition (breaths per minute; M=19, SD=2.4) than placebo (M=20.5, 
SD=2). This is within the normal range, as average respiration is 14-20 breaths/minute in 
healthy adults (Lindh, Pooler, Tamparo, Dahl, & Morris, 2013). Average heart rate was 77 
(SD=12) beats per minute for morphine and 75 (SD=10) for placebo.  
fMRI results 
Due to the low sample size (N=11) we visually inspected all individual first level 
FEAT analyses to check for outliers. Pre-processing parameters and results for each 
individual run were inspected to assure the quality of registration, and to evaluate movement 
and model fit. All functional images were successfully registered both to individual high-
resolution images and MNI standard space. There was minimal movement in all time series, 
resulting in no excluded data points in the current analysis (absolute movement <0.76mm for 
all participants).  
Checkerboard paradigm.  Fixed effects analyses in the placebo and morphine 
conditions showed that the flickering checkerboards induced significant activation in visual 
areas. For both conditions, significant clusters were identified in the occipital cortex (maxium 
Z-scores: Z= 24.6 (morphine) and Z= 20.2 (placebo); see Figure 10). Contrasting the two 
conditions revealed a significantly higher activation in the fusiform gyrus of the temporal 
lobe in the morphine condition (Z= 3.37). Given the comparable activations in the task-
relevant occipital lobe, we find no indication of drug effects on overall BOLD sensitivity.  
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MID task.  
Whole-brain analysis. All activation peaks and coordinates reported below are listed 
in Table 2. 
Anticipation of gain.  In the placebo condition, anticipation of monetary gain 
(contrast: positive cues > neutral cues) induced significant activation clusters in the striatum, 
occipital cortex and the frontal gyrus (Figure 11a). In the morphine condition, significant 
clusters were found in the striatum, the occipital cortex, and postcentral gyrus (Figure 11a). 
In the morphine > placebo contrast, no activations survived cluster thresholding. In the 
placebo > morphine contrast, there were significant clusters identified in the precuneus and 
cerebellum.  
 
 
Checkerboard > rest 
Morphine Placebo 
Placebo > morphine Morphine > placebo 
X= 16 X= 16 
X= -24 X= 12 
Figure'10."Significant"activations"in"the"checkerboard"paradigm,"with"visual"stimuli"
modelled"against"rest"(baseline)."Activation"for"the"morphine"condition"is"presented"in"redI
yellow,"placebo"in"blue."Bottom"row"shows"significant"activation"in"the"contrasts"morphine"
>"placebo"(left)"and"placebo">"morphine."MNI"slice"coordinates"are"displayed"on"the"left"
side"of"the"images."Activation"clusters"are"thresholded"at"Z>"2.3."
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Anticipation of loss. In the placebo condition, anticipation of monetary loss (contrast: 
negative cues > neutral cues) elicited significant activation in the occipital lobe and the 
superior parietal lobule (SPL)(Figure 11b). In the morphine condition, significant activation 
clusters were identified in the putamen, occipital lobe, SPL, temporal gyrus, and the 
cerebellum (Figure 11b). The contrasts morphine > placebo and placebo > morphine yielded 
no significant activation clusters. 
Successful and non-successful outcome.  For the placebo condition, successful 
outcomes (contrast: successful trials > non-successful trials) activated the striatum as well as 
frontal cortex, cerebellum, SPL, and frontal gyrus (Figure 12a). In the morphine condition, 
the striatum, frontal cortex, and occipital lobe were significantly activated (Figure 12a). In 
the drug contrasts, significant clusters were identified in the SPL and precuneus in the 
morphine > placebo contrast only. However, visual inspection of below-threshold activation 
maps indicated group differences in striatal areas that did not survive cluster thresholding. 
Using small volume correction (with voxel-based correction) within the a priori defined left 
putamen ROI mask, voxels in the ventral putamen survived correction for multiple 
comparisons at the p=0.05 level in the morphine > placebo contrast (but not in the placebo > 
morphine contrast; Figure 12b). 
Figure'11."Brain"activity"elicited"by"visual"cues"indicating"potential"gain"(a),"and"potential"
loss"(b)"in"the"monetary"incentive"delay"task"for"morphine"(redIyellow)"and"placebo"(blue)"
conditions."Slice"coordinates"are"displayed"to"the"left"of"the"figures"(in"MNI"standard"
space),"and"the"left"side"of"the"images"correspond"to"the"right"side"of"the"brain."Activation"
clusters"are"thresholded"at"Z>2.3."
a' b'
Positive > neutral 
Morphine Placebo 
Z= 0 
Y= 0 
Z= 0 
Y= 8 
Negative > neutral 
Morphine Placebo 
Y= 8 
Z= 0 Z=0 
Y= 8 Y= 8 Y= 8 
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Table&2
Regions&activated&for&the&different&contrasts&in&the&whole6brain&analysis.
Contrast Condition Area
Positive&cues&>&neutral&cues Morphine Occipital&cortex
Putamen&(L),&thalamus&(L),&Putamen&(R&)
Postcentral&gyrus
Postcentral&gyrus
Placebo Occipital&cortex
Middle&frontal&gyrus
Pallidum,&putamen&(L),&OFC&(R&)
Negative&cues&>&neutral&cues Morphine Occipital&cortex
Superior&parietal&lobule
Middle&temporal&gyrus
Putamen&(L)
Occipital&cortex
Cerebellum
Placebo Occipital&pole
Superior&parietal&lobule
Successful&>&non6successful&trials Morphine Occipital&cortex
Frontal&pole
Putamen&(L&)
Placebo Frontal&pole
Cerebellum
Superior&parietal&lobule
Superior&parietal&lobule
Nucleus&accumbens,&putamen&(R&)
Inferior&frontal&gyrus
Drug&contrasts
Positive&cues&>&neutral Morphine&>&Placebo 6
Placebo&>&Morphine Precuneus
Cerebellum
Negative&cues&>&neutral Morphine&>&Placebo 6
Placebo&>&Morphine 6
Successful&>&non6successful&trials Morphine&>&Placebo Postcentral&gyrus
Precuneus
Placebo&>&Morphine 6
Note.&Cluster6based&activations&in&the&contrasts&of&interest&for&each&drug&condition,&and&the&contrasts&morphine&>&placebo&and&placebo&>&morphine.&
Peak&coordinates&in&Montreal&Neurological&Institue&(MNI).&All&activations&are&cluster&thresholded&at&Z&>&2.3&and&corrected&for&multiple&comparisons&at&
the&p<0.05&level.&
#&of&voxels
Max&Z6
score Z &Y &Z&
5363 8.76 16 692 610
2736 4.42 626 610 4
1862 4.36 644 622 56
1225 3.78 48 622 44
16209 7.04 12 694 68
945 5.03 640 20 24
459 4.34 618 4 64
13804 7.69 12 6102 4
1321 4.14 38 640 54
651 3.31 42 644 4
511 3.82 626 4 4
508 3.3 10 682 16
424 3.91 638 670 648
20537 7.54 14 6102 8
1298 4.15 638 646 56
33228 6.64 46 670 640
3471 5.83 62 64 8
555 5.99 620 8 610
5138 5.29 646 48 14
2070 5.53 44 672 638
1054 4.05 646 650 62
964 5.22 622 28 54
686 4.7 12 12 68
625 4.42 24 12 26
2427 4.13 24 652 26
1519 3.86 62 646 620
1452 4.5 20 642 68
742 4.24 0 662 48
Peak&voxel
Figure'12."(a)"Significant"activation"clusters"in"the"morphine"(redIyellow)"and"placebo"(blue)"
conditions"for"successful"versus"nonIsuccessful"outcomes"regardless"of"associated"trial"valence."
Slice"coordinates"are"displayed"to"the"left"of"the"images"(in"MNI"standard"space),"and"the"left"
side"of"the"images"correspond"to"the"right"side"of"the"brain."Activations"are"cluster"thresholded"
at"Z>"3"for"illustration"purposes."(b)"Voxels"activated"in"the"contrast"morphine">"placebo"for"
successful"versus"nonIsuccessful"outcome"in"the"ventral"striatum,"identified"using"small"volume"
correction"inside"the"left"putamen"mask"(MNI"coordinates:"I15,"9,"I6;"a"priori"ROI)."Maximum"ZI
score"="3.2,"p<0.05."Left"side"of"image"corresponds"to"right"side"of"the"brain."
"
a' b'
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ROI analysis.  Analysis of mean signal change within the a priori defined ROIs 
showed a significant main effect of cue type in the left (F(4, 40)= 2.63, p= .047, !!!=.209) 
and right (F(4,40)= 6.00, p= .001, !!=.375) putamen for the anticipation phase of the MID 
task (Figure 13). There were no significant effects of drug or drug*cue interactions in this or 
any other ROIs for the anticipation phase. In the outcome phase there were no significant 
effects of cue type or drug condition for successful trials. In the analysis of successful versus 
non-successful trials there was a significant main effect of outcome in the left putamen 
(F(1,10)= 15.44, p=.003, !!=.607), right putamen (F(1,10)= 12.51, p=.005, !!=.556), left 
NAc (F(1,10)= 11.85, p=.006, !!=.542), right NAc (F(1,10)= 16.40, p=.002, !!=.621), and 
right insula (F(1,10)= 6.22, p=.032, !!=.384), illustrated in Figure 14. There was also a 
significant main effect of drug in the left putamen (F(1,10)= 6.16, p=.032, !!=.381), but no 
significant drug*outcome interaction.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure'13."Main"effect"of"cue"type"on"mean"signal"change"for"each"cue"type"during"
anticipation"in"the"right"and"left"putamen."Cue"type"is"indicated"by"the"monetary"value"
associated"with"each"cue"in"Norwegian"kroner"(NOK)."Error"bars"represent"withinIsubjects"
standard"error"of"the"mean"(SEM)."
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Discussion 
The main aim for the current pilot study has been to develop a set of procedures to 
investigate the effect of opioid manipulation on reward behaviour and brain processes. Based 
on the special consideration pharmacological fMRI studies require, a test battery has been 
developed and data from 11 healthy participants under two drug conditions was collected and 
analysed. Our main experimental outcome measure was brain activation during the MID 
paradigm. We wanted to ensure that our paradigm could be successfully used to measure 
reward behaviour and ultimately to assess potential changes associated with µ-opioid receptor 
manipulation. A range of control tasks and measures were included to test for potential 
confounds introduced by the pharmacological fMRI design. Based on this data, a large 
pharmacological fMRI study will be founded (N= 50-60).  
A large part of this thesis has been to adapt the MID task to assess opioid effects on 
BOLD responses to reward. Analyses validated that our MID task version did elicit activity 
in the ventral striatum during anticipation of both monetary rewards and losses as well as 
delivery of rewards in both drug conditions. In a priori defined ROIs in the bilateral ventral 
putamen, significant main effects of cue type were observed in anticipation of reward. The 
bilateral ventral putamen, NAc, and the right insula ROIs also showed significant difference 
in activation between successful and non-successful outcomes. These results are in line with 
previous studies regarding activity in striatal regions during reward processing, and validates 
the modified MID task used in this study. Control measures indicated no systematic effects of 
Figure'14."Main"effect"of"MID"task"outcome"in"the"five"a"priori"ROIs"(regions"of"interest)."
Successful"refers"to"all"trials,"regardless"of"incentive"cues,"that"the"participants"successfully"
responded"to."NonIsuccessful"refers"to"trials"where"no"response"was"detected,"or"was"given"
outside"of"the"response"window."NAc="nucleus"accumbens."Error"bars"represent"withinI
subject"standard"error"of"the"mean"(SEM)."
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morphine on general task performance or BOLD response, supporting the current drug 
administration protocol. In this pilot study, we also compared healthy volunteers on morphine 
and placebo to see if we could detect an effect of µ-opioid receptor agonism on BOLD 
activation in the MID task. The results showed few significant effects of morphine on task 
activation, but there was an effect of drug in the expected direction (morphine > placebo) in 
the left ventral putamen for successful outcomes. These preliminary results are promising for 
the main study of opioid effects on reward processing.  
Choice of regions of interest   
The choice of ROIs in the current study was based on regions identified in a meta-
analysis of MID task results produced in relation to the ongoing ICCAM Platform Study. The 
brain regions identified were in line with an earlier MID task meta-analysis (Knutson & 
Greer, 2008), and studies using other reward tasks (Delgado, 2007; Liu et al., 2011). NAc and 
other striatal regions are often reported in reward studies using fMRI, but the exact location 
and definition of ROIs varies between studies. For this reason, it is often recommended to 
define ROIs based on meta-analyses of relevant data rather than single peak activations from 
one study (Poldrack, 2007). Hypothesis based ROIs are also less biased than defining areas of 
interest post hoc (Vul, Harris, Winkielman, & Pashler, 2009). We used the regions identified 
in the most recent of the two meta-analyses available on MID task data (McGonigle, ICCAM 
Platform Study meta-analysis, obtained through personal communication). We cross-
referenced the locations of our chosen ROIs with other studies and found that our ROIs in the 
left and right putamen overlapped with more than half of reported striatum peak coordinates 
in a review by Balodis and Potenza (2014). This indicates that our choice of ROIs was 
consistent with previous literature, and our findings of significant activation in the putamen 
correspond to other studies that report activation in the ventral striatum. In future analyses it 
is possible to include other ROIs relevant for reward, such as the OFC. The OFC and the 
mPFC have been implicated especially in the outcome phase of the MID task (Knutson et al., 
2003), and previous studies have found that these regions respond specifically to the highest 
and lowest valued rewards as compared to mid-range rewards (Elliott, Newman, Longe, & 
Deakin, 2003). In the current study we observed activations in the OFC in the whole-brain 
analyses. We did not investigate this further in the preliminary ROI analysis, as the primary 
goal for this thesis was to validate the task and protocol to be used in a larger study. This 
brain region is of interest for further exploration, especially in the context of parametric 
variation of reward values. 
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In addition to activation in reward-related areas, we also observed significant 
activation clusters in visual and sensory-motor areas in all contrasts of interest. This could be 
explained by increased salience or attention towards the incentive cues compared with the 
neutral trials, and more conscious effort exerted towards responding to the stimuli.  
Validation of the current MID paradigm 
During the MID task development we considered a range of different options and 
psychometric properties of task designs used in earlier studies, each one influencing the 
possible analyses and comparisons that could be made (e.g. Bjork et al., 2008a; Knutson et 
al., 2001b; Pizzagalli et al., 2009). We modified the task to create a version that could be 
used to investigate anticipation of both gain and loss, would allow parsing of anticipation and 
delivery of reward, and could be adapted for use with different patient populations and other 
populations of varying cognitive ability. Therefore, we needed to ensure that both 
behavioural and imaging results would compare to previous studies. 
As expected, the behavioural results yielded no significant differences across session 
or drug conditions, indicating that there was no learning effect or drug effect on task 
performance. This is consistent with previous studies (e.g. Beck et al., 2009; Jia et al., 2011; 
Knutson et al., 2001b; Scheres et al., 2007). These results show that the adaptive algorithm in 
the task itself, as well as the adjustment to individual reaction times, successfully kept 
accuracy rates stable across participants and conditions. We did observe higher accuracy rates 
for the high positive cue than the low positive cue, and this was expected since the task was 
designed to yield 66% accuracy for each valence condition and not per cue (meaning that the 
small and large incentive cues were combined). This was done to have enough repetitions of 
each trial type for effective task titration. In fact, the higher accuracy for the higher reward 
further supports the validity of the task design, as it can indicate that participants were more 
motivated to respond for high rewards than low rewards. The most important aspect of the 
behavioural results was to show comparable performance across all conditions, as an equal 
performance and high (and stable) success rate is necessary for the MID task to successfully 
elicit reward-related activity (K. Lutz & Widmer, 2014). Having established this in our 
current paradigm, the next step was to ensure that the task elicited activity in reward related 
brain regions identified in both the hypotheses and previous studies.  
The results from this pilot study are based on a small sample with low detection 
power, and must therefore be considered preliminary. Using fixed effects analysis, we found 
significant activation in striatal areas for anticipation of both gains and losses, and to 
successful outcomes. This is consistent with previous studies using the MID task that have 
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found striatal activation to anticipation and outcome phases (Admon et al., 2014; Bustamante 
et al., 2014; Dillon et al., 2008; Kumar et al., 2014; Pizzagalli et al., 2009). The first studies 
by Knutson and colleagues  (2001; 2003; 2004) focused primarily on the role of the NAc in 
anticipation of gain. Later studies have found that other areas related to the striatum/basal 
ganglia complex are also activated in the MID task, such as the caudate (Pizzagalli et al., 
2009), putamen (Beck et al., 2009), and pallidum (Kumar et al., 2014). In addition, the insula 
has been implicated in anticipation and delivery of losses (Bjork et al., 2008b; Nestor et al., 
2010), the OFC and mPFC in the outcome stages of the task (Bjork et al., 2008b; Knutson et 
al., 2001b; Simon et al., 2010), and the thalamus in anticipation (Cho et al., 2013; Jia et al., 
2011).  
Anticipation.  In the current study we found significant activation the bilateral 
putamen, pallidum, thalamus, caudate and OFC in both drug conditions during anticipation of 
both gains and losses. In the ROI analyses we did not find a significant effect of cue type in 
the NAc ROIs in the anticipatory phase. We did find that cue type affected signal change in 
the ventral putamen, however, with higher signal change to gain and loss cues compared to 
the neutral cues. Notably, the ROIs defined in the current study are not identical to those used 
previously, as these also differ between studies. It is possible that activations in similar areas 
have been labelled differently due to close proximity of the NAc and putamen in the VS.  
Activation of the ventral putamen in anticipation of reward is consistent with previous 
studies using the MID task (Beck et al., 2009; Knutson et al., 2001a; Knutson et al., 2004; 
Knutson & Greer, 2008; Kumar et al., 2014; Simon et al., 2010). This VS activation to 
anticipation of reward has been previously linked to motivational and saliency aspects of 
rewarding stimuli (Delgado et al., 2000; Liu et al., 2011), as well as prediction of reward in 
response to cues depending on valence and magnitude (K. Lutz & Widmer, 2014). The VS 
activation to positive and negative cues observed in the current study is therefore in line with 
the assumption that these incentive cues induce an expectation of a particular outcome 
(reward or punishment) that the neutral cues do not. 
Outcome.  A primary aim for the current task development was to allow for separate 
analysis of anticipation and outcome phases of reward. For the outcome, we were interested 
in brain areas that were activated more to successful than non-successful outcomes. This 
contrast included all cue-conditions to allow for a more robust analysis due to the lower 
number of non-successful trials (~33% vs ~66%). Voxels in the ventral putamen and NAc 
showed significantly higher activation in the successful trials compared to the non successful. 
In the ROI analysis, we identified significant differences in mean signal change between 
MORPHINE EFFECTS ON MONETARY REWARD 
 
40 
correct and incorrect trials in all of the a priori regions of interest. This shows that a 
successful outcome is probing activity in reward related areas consistent with previous 
studies (Dillon et al., 2008; Pizzagalli et al., 2009; Simon et al., 2010). We observed that 
while the striatal ROIs were more activated for correct than incorrect outcomes, the right 
insula ROI showed the opposite pattern. This is consistent with previous findings using the 
MID task (Bjork et al., 2008b) and the literature implicating the insula particularly for 
negatively valenced rewards (Liu et al., 2011).  
In sum, we observed activation clusters around the ventral/dorsal striatum in the 
whole-brain analysis for both anticipation and delivery of rewards, and we are satisfied that 
the current task measures up to previous versions. 
Using the MID task to study morphine effects 
To allow for interpretation of potential drug effects on brain activity or task 
performance, we included a range of control tasks and measures in the current study to rule 
out confounding variables related to the pharmacological manipulation. Having established 
that the task elicited detectable activation in reward-related regions in both drug conditions, 
we were satisfied that the task was appropriate for studying reward processing. We then 
investigated the effects of morphine on brain activity related to monetary gain and loss. µ-
opioid receptor agonism has been found previously to increase reinforcing effects and 
decrease aversive effects of rewards and punishment (and pain) in humans and animals 
(Chelnokova et al., 2014; P.E. Lutz & Kieffer, 2013; R.G. Wise et al., 2002). In our pilot 
sample of 11 volunteers, we did not find significant effects of morphine that survived cluster 
thresholding and correction for multiple comparisons in the whole brain analysis. We did, 
however, find trends suggesting an increase in reward related brain activity for successful 
outcomes in the morphine condition in an exploratory analysis applying correction for 
multiple comparisons only within the a priori defined left ventral putamen mask. While this 
result is not sufficient to make inferences about the meaning of these effects, it is 
encouraging as there could be significant effects in a larger sample with sufficient power.  
Drug dose and subjective effects.  The morphine dose given in the current study was 
chosen to stimulate µ-opioid receptors without affecting task performance or give serious side 
effects. Previous studies in our laboratory have shown that the same dose of morphine 
influences response bias (Eikemo, 2011) and attractiveness ratings of faces (Chelnokova et 
al., 2014), while not affecting subjective experience. When we compared subjective ratings 
of feeling ‘high’ and feeling effects of drugs in the current study, we found no differences 
between drug conditions. This renders it unlikely that participants’ performance in the reward 
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task was influenced by expectation or drug effects on cognitive abilities. Previous studies 
have found that most people experience no serious side effects with morphine doses up to 60 
mg (Walker & Zacny, 1998; Zacny & Lichtor, 2008). In the current study, one participant 
experienced aversive side effects at the end of the morphine session (included in study 
sample) and another during the placebo session (withdrew from study). This indicates no 
consistent side effects associated with the current drug dose. 
Motor coordination.  Opioids assert some of their effects in the brain through 
interactions with DA neurons in the mesolimbic system (Nestler, 2005). In addition to being 
implicated in reward and motivation, mesolimbic DA is also important for movement and 
execution of motoric responses (Obeso, Rodriguez-Oroz, Stamelou, Bhatia, & Burn, 2014).  
In a study by Pizzagalli et al. (2008), a low dose of DA agonist affected both reward 
sensitivity and motor speed. In the MID task, the delivery of reward is reliant on a fast 
response from participants at the right time (target presentation). While the task is titrated to 
an individual’s average response time, there is a pre-determined window of time in which a 
response has to be made. We therefore included the BRAIN test (Giovannoni et al., 1999) as 
a control task to make sure that potential slowing of motoric responses caused by drug 
condition did not affect task performance and consequently delivery of rewards. Compared to 
placebo, morphine did not influence motor speed or coordination in the current study. This is 
in line with results from previous studies in our laboratory using the same morphine dose 
(Chelnokova et al., 2014; Eikemo, 2011), and behavioural results from the MID task showing 
no differences in accuracy or reaction times between the two drug conditions.  
Effect of drug manipulation on BOLD response.  One of the main concerns when 
planning a pharmacological fMRI study is to ensure that the pharmacological manipulation 
by itself does not alter the ability to detect significant activations. Opioids can cause 
respiratory depression and consequently reduce detectability of task-relevant BOLD signals 
(Cohen et al., 2002; MacIntosh et al., 2008; K. Pattinson, 2008). We recorded respiration and 
heart rate during fMRI scanning in both conditions drug, and observed a small but significant 
reduction in respiration rate in the morphine condition compared to placebo. This could be 
due to opioid effects on respiratory systems. This analysis was based on a sample of only six 
participants and the difference in means was relatively small. It is therefore not appropriate to 
draw conclusions based on these results, and it is not clear whether this difference in mean 
respiration would be enough to affect BOLD signal sensitivity. Correcting for physiological 
variance by including average heart rate and respiration rate in higher level fMRI analysis has 
been found to significantly improve BOLD results (Brooks et al., 2008; Khalili-Mahani et al., 
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2013). In the main study following this pilot, physiological recordings will be included in the 
analyses. It is also worth noting that while it has been recommended to monitor breathing to 
make sure it does not drop below 6 breath/minute after morphine administration (Becerra et 
al., 2006), the mean for both conditions in the current study was closer to 20 breaths/minute. 
Breathing frequencies less than 8-10 breaths/minute is considered respiratory depression 
(Dahan, Aarts, & Smith, 2010), and we find no evidence of this in our participants who are 
all within normal range (Lindh et al., 2013). It is therefore too early to interpret the 
physiological findings, and we will need to address this at a later point in the data collection. 
It is possible to control for respiratory depression effects by supplying oxygen to participants, 
and monitor end-tidal CO2 to get a more accurate measure of respiratory effects on BOLD 
signal (Khalili-Mahani et al., 2012).  
We also included a visual fMRI paradigm in our test battery to examine the potential 
confound of respiratory depression. The visual checkerboard stimuli induced significant 
activation in visual areas for both morphine and placebo conditions. There was no difference 
between drug conditions in the visual cortex, and the only significant difference between 
morphine and placebo was an activation cluster in the fusiform gyrus (morphine > placebo) 
Considering the small sample size in the current study, this could be due to variation 
unrelated to drug condition. The visual cortex was the primary area of interest for the control 
task (checkerboard), and this area, unlike more temporal regions such as the fusiform, has a 
negligible distribution of opioid receptors (Baumgärtner et al., 2006; Frost et al., 1989; 
Liberzon et al., 2002). The occipital cortex is therefore a good point of reference for 
assessing opioid effects on BOLD response, and any general morphine effects would be 
expected to result in activations in the placebo > morphine contrast in this area.  
We did not observe any such effects, and as such there are no indications that the 
current morphine dose has any effects on respiration and/or BOLD response that influences 
the ability to detect changes in reward task activation. 
Limitations and future research 
The current findings are based on preliminary data from a pilot study and as such 
there are limitations on what inferences can be drawn from the results. As the main aim was 
to validate the task and procedures, the finding of ventral striatum activation to anticipation 
and delivery of rewards was in line with previous literature and does not directly provide any 
new knowledge about the reward system. One of the problems with the fMRI research using 
the MID task, and with a lot of fMRI research in general, is that many published studies have 
low power due to small sample sizes. Therefore, just replicating findings of previous studies 
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using the MID task is good task validation as there are many inconsistencies in previous 
literature.  
Although our sample of 11 is relatively small, we utilised a within-subjects design 
which makes it more powerful than a similar sample size tested between subjects. However, 
we did not have power to analyse gender effects in this pilot study. Morphine can interact 
with female sex hormones dependent on the time of the menstrual cycle (Ribeiro-Dasilva et 
al., 2011). We tried to keep conditions as consistent as possible for the females included in 
the sample, and all females were tested within a time frame of maximum four days to avoid 
testing at radically different phases in the menstrual cycle. However, we cannot be certain 
that no hormonal changes took place within this testing interval in the two participants who 
did not use hormonal contraception, since they were unfortunately unable to determine the 
timing since their last menstruation. In a larger sample it would be of interest to test for 
gender effects and control for influence of menstrual cycle and contraception on morphine 
effects. 
The current study also used a pre-selected dose of morphine, and we did not 
individually titrate dosage to ensure similar blood concentrations of drug between 
participants. However, this is less important due to the within subjects design than it would 
be in a study comparing different groups of participants. Future studies could also investigate 
dose-response effects of morphine on reward related activity, while still monitoring and 
controlling for respiratory effects, or include results from blood samples in FEAT analysis.  
In terms of the MID task, we developed a task that was powered to look at both wins 
and losses and allowed parsing of anticipation and outcome. While we did not fully explore 
all the contrasts available in the current pilot study, it is possible to investigate differences or 
similarities in activity elicited by winning and losing in the future.  
This is also the first implementation of the MID task in Norwegian, and it could 
therefore be of interest to adjust the values associated with the different cues. The current 
values (1 and 5 NOK) were similar to studies using other currencies, but the value of these 
small monetary sums might not be sufficient to elicit strong effects in our sample. High 
income and cost of living in Norway may render these monetary sums relatively smaller than 
the corresponding US dollar or Euro values. The “real” value of money depends on 
subjective value attributions (Kable & Glimcher, 2007), and it could be that the subjective 
values of the cues in the current study do not cover a large enough range to obtain strong 
effects. This could also explain the weak parametric variation in brain activations to different 
anticipation cues within the striatum in the current study compared to earlier findings 
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(Knutson et al., 2001a; Knutson & Greer, 2008). In the continuation of the study we will 
include a measure of subjective ratings and happiness associated with the different MID cues 
that the participants will complete at the end of each session. This will give an indicator of 
how the participants value the different rewards, and it will allow for a comparison of 
subjective experience of winning versus losing that could be valuable for further analysis of 
these two conditions separately. 
We did not apply B0 field map correction to the fMRI data in the current study. This 
could improve functional data quality as it reduces noise from magnetic field 
inhomogeneities (Jezzard, 2012). An alternative method to traditional B0 field map scans, 
which take several minutes, is to include short ‘reversed-blip’ scans and use these to correct 
for distortions (for a comprehensive explanation of this method see Andersson, Skare, & 
Ashburner, 2003). This can be implemented in analyses using the FSL TOPUP tool. We are 
currently in the process of setting up a protocol for the use of TOPUP in fMRI analysis, and 
this will be applied to the current data set (appropriate scans were recorded at the time of 
testing) and to the additional data collected in the continuation of the project.  
Conclusion 
In the current pilot study we developed a protocol for a pharmacological fMRI 
investigation of the role of the opioid system in reward processing in the healthy human 
brain. The MID task successfully activated areas implicated in previous research. 
Specifically, we observed ventral striatal activation to monetary rewards in both of our drug 
conditions, as well as indications of a possible morphine effect in the reward outcome 
contrast. This is consistent with the overarching research hypothesis that systemic 
manipulation of the µ-opioid receptor system can increase reward related brain activity in the 
ventral striatum to delivery of rewards. The reward task and control measures in the current 
pilot study will be used in the main pharmacological study. With a larger sample size and 
more definite results, the main study can provide further insight into the role of the µ-opioid 
receptor system in reward processing in the brain and have implications for our 
understanding of addiction and affective psychopathologies.  
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